

22105974D

SENATE BILL NO. 591

AMENDMENT IN THE NATURE OF A SUBSTITUTE

(Proposed by the Senate Committee on Rehabilitation and Social Services
on February 4, 2022)

(Patron Prior to Substitute—Senator Hanger)

A BILL to amend and reenact §§ 3.2-4113, 3.2-4118, 4.1-600, 4.1-606, 9.1-1101, 18.2-247, 18.2-251.1, 19.2-188.1, 54.1-3401, 54.1-3408.3, 54.1-3423, 54.1-3442.6, 54.1-3442.7, 54.1-3446 of the Code of Virginia, relating to marijuana; shape prohibitions; definitions of marijuana and tetrahydrocannabinol.

Be it enacted by the General Assembly of Virginia:

1. That §§ 3.2-4113, 3.2-4118, 4.1-600, 4.1-606, 9.1-1101, 18.2-247, 18.2-251.1, 19.2-188.1, 54.1-3401, 54.1-3408.3, 54.1-3423, 54.1-3442.6, 54.1-3442.7, 54.1-3446 of the Code of Virginia are amended and reenacted as follows:

§ 3.2-4113. Production of industrial hemp lawful.

A. It is lawful for a grower, his agent, or a federally licensed hemp producer to grow, a dealer or his agent to deal in, or a processor or his agent to process industrial hemp in the Commonwealth for any lawful purpose. No federally licensed hemp producer or grower or his agent shall be prosecuted under Chapter 11 (§ 4.1-1100 et seq.) of Title 4.1 or § 18.2-247, 18.2-248, 18.2-248.01, 18.2-248.1, or 18.2-250 for the possession or growing of industrial hemp or any Cannabis sativa with a tetrahydrocannabinol concentration that does not exceed the total ~~delta-9~~ tetrahydrocannabinol concentration percentage established in federal regulations applicable to negligent violations located at 7 C.F.R. 990.6(b)(3). No dealer or his agent or processor or his agent shall be prosecuted under Chapter 11 (§ 4.1-1100 et seq.) of Title 4.1 or § 18.2-247, 18.2-248, 18.2-248.01, 18.2-248.1, or 18.2-250 or issued a summons or judgment for the possession, dealing, or processing of industrial hemp. In any complaint, information, or indictment, and in any action or proceeding brought for the enforcement of any provision of Chapter 11 (§ 4.1-1100 et seq.) of Title 4.1 or Article 1 (§ 18.2-247 et seq.) of Chapter 7 of Title 18.2 or the Drug Control Act (§ 54.1-3400 et seq.), it shall not be necessary to negate any exception, excuse, proviso, or exemption contained in this chapter or the Drug Control Act, and the burden of proof of any such exception, excuse, proviso, or exemption shall be on the defendant.

B. Nothing in this chapter shall be construed to authorize any person to violate any federal law or regulation.

C. No person shall be prosecuted under Chapter 11 (§ 4.1-1100 et seq.) of Title 4.1 or § 18.2-247, 18.2-248, 18.2-248.01, 18.2-248.1, or 18.2-250 for the involuntary growth of industrial hemp through the inadvertent natural spread of seeds or pollen as a result of proximity to a production field, dealership, or process site.

§ 3.2-4118. Forfeiture of industrial hemp grower, dealer, or processor registration; violations.

A. The Commissioner shall deny the application, or suspend or revoke the registration, of any person who, with a culpable mental state greater than negligence, violates any provision of this chapter. The Commissioner shall provide reasonable notice of an informal fact-finding conference pursuant to § 2.2-4019 to any person in connection with the denial, suspension, or revocation of a registration.

B. If a registration is revoked as the result of an informal hearing, the decision may be appealed, and upon appeal an administrative hearing shall be conducted in accordance with the Administrative Process Act (§ 2.2-4000 et seq.). The grower, dealer, or processor may appeal a final order to the circuit court in accordance with the Administrative Process Act.

C. A person issued a registration pursuant to subsection A of § 3.2-4115 who negligently (i) fails to provide a description and geographic data sufficient for locating his production field, dealership, or process site; (ii) grows, deals in, or processes Cannabis sativa with a tetrahydrocannabinol concentration greater than that allowed by federal law; or (iii) produces a Cannabis sativa product shall comply with any corrective action plan established by the Commissioner in accordance with the provisions of subsection E. The Commissioner shall not deem a grower negligent if such grower makes reasonable efforts to grow industrial hemp and grows Cannabis sativa with a tetrahydrocannabinol concentration that does not exceed the total ~~delta-9~~ tetrahydrocannabinol concentration percentage established in federal regulations applicable to negligent violations located at 7 C.F.R. 990.6(b)(3).

D. A person who grows, deals in, or processes industrial hemp and who negligently fails to register pursuant to subsection A of § 3.2-4115 shall comply with any corrective action plan established by the Commissioner in accordance with the provisions of subsection E.

E. A corrective action plan established by the Commissioner in response to a negligent violation of a provision of this chapter shall identify a reasonable date by which the person who is the subject of the plan shall correct the negligent violation and shall require such person to report periodically for not less

60 than two calendar years to the Commissioner on the person's compliance with the provisions of this
61 chapter.

62 F. No person who negligently violates the provisions of this chapter three times in a five-year period
63 shall be eligible to grow, deal in, or process industrial hemp for a period of five years beginning on the
64 date of the third violation.

65 **§ 4.1-600. Definitions.**

66 As used in this subtitle, unless the context requires a different meaning:

67 "Advertisement" or "advertising" means any written or verbal statement, illustration, or depiction
68 that is calculated to induce sales of retail marijuana, retail marijuana products, marijuana plants, or
69 marijuana seeds, including any written, printed, graphic, digital, electronic, or other material, billboard,
70 sign, or other outdoor display, publication, or radio or television broadcast.

71 "Authority" means the Virginia Cannabis Control Authority created pursuant to this subtitle.

72 "Board" means the Board of Directors of the Virginia Cannabis Control Authority.

73 "Cannabis Control Act" means Subtitle II (§ 4.1-600 et seq.).

74 "Child-resistant" means, with respect to packaging or a container, (i) specially designed or
75 constructed to be significantly difficult for a typical child under five years of age to open and not to be
76 significantly difficult for a typical adult to open and reseal and (ii) for any product intended for more
77 than a single use or that contains multiple servings, resealable.

78 "Cultivation" or "cultivate" means the planting, propagation, growing, harvesting, drying, curing,
79 grading, trimming, or other similar processing of marijuana for use or sale. "Cultivation" or "cultivate"
80 does not include manufacturing or testing.

81 "Edible marijuana product" means a marijuana product intended to be consumed orally, including
82 marijuana intended to be consumed orally or marijuana concentrate intended to be consumed orally.

83 "Immature plant" means a nonflowering marijuana plant that is no taller than eight inches and no
84 wider than eight inches, is produced from a cutting, clipping, or seedling, and is growing in a container.

85 "Licensed" means the holding of a valid license granted by the Authority.

86 "Licensee" means any person to whom a license has been granted by the Authority.

87 "Manufacturing" or "manufacture" means the production of marijuana products or the blending,
88 infusing, compounding, or other preparation of marijuana and marijuana products, including marijuana
89 extraction or preparation by means of chemical synthesis. "Manufacturing" or "manufacture" does not
90 include cultivation or testing.

91 "Marijuana" means (i) any part of a plant of the genus *Cannabis*, whether growing or not, its seeds
92 or resin; and every compound, manufacture, salt, derivative, mixture, or preparation of such plant, its
93 seeds, its resin, or any extract containing one or more cannabinoids or (ii) *any substance containing a*
94 *total tetrahydrocannabinol concentration that exceeds 0.3 percent, including a hemp product, as defined*
95 *in § 3.2-4112, or an industrial hemp extract, as defined in § 3.2-5145.1.* "Marijuana" does not include
96 (a) the mature stalks of such plant, fiber produced from such stalk, or oil or cake made from the seed of
97 such plant, unless such stalks, fiber, oil, or cake is combined with other parts of plants of the genus
98 *Cannabis*; ~~"Marijuana" does not include (i);~~ (b) industrial hemp, as defined in § 3.2-4112, that is
99 possessed by a person registered pursuant to subsection A of § 3.2-4115 or his agent ~~or (ii);~~ (c)
100 *industrial hemp, as defined in § 3.2-4112, that is possessed by a person who holds a hemp producer*
101 *license issued by the U.S. Department of Agriculture pursuant to 7 C.F.R. Part 990 or his agent;* (d) a
102 hemp product, as defined in § 3.2-4112, containing a tetrahydrocannabinol concentration of no greater
103 than 0.3 percent that is derived from industrial hemp, as defined in § 3.2-4112, that is grown, dealt, or
104 processed in compliance with state or federal law; (e) *an industrial hemp extract, as defined in*
105 *§ 3.2-5145.1, containing a tetrahydrocannabinol concentration of no greater than 0.3 percent that is*
106 *derived from industrial hemp, as defined in § 3.2-4112, grown, dealt, or processed in compliance with*
107 *state or federal law; or (f) any drug product containing tetrahydrocannabinol that is approved for*
108 *marketing by the U.S. Food and Drug Administration and scheduled in the Drug Control Act*
109 *(§ 54.1-3400 et seq.) by the Board of Pharmacy pursuant to § 54.1-3443.*

110 "Marijuana concentrate" means marijuana that has undergone a process to concentrate one or more
111 active cannabinoids, thereby increasing the product's potency. Resin from granular trichomes from a
112 marijuana plant is a concentrate for purposes of this subtitle.

113 "Marijuana cultivation facility" means a facility licensed under this subtitle to cultivate, label, and
114 package retail marijuana; to purchase or take possession of marijuana plants and seeds from other
115 marijuana cultivation facilities; to transfer possession of and sell retail marijuana, immature marijuana
116 plants, and marijuana seeds to marijuana wholesalers and retail marijuana stores; to transfer possession
117 of and sell retail marijuana, marijuana plants, and marijuana seeds to other marijuana cultivation
118 facilities; to transfer possession of and sell retail marijuana to marijuana manufacturing facilities; and to
119 sell immature marijuana plants and marijuana seeds to consumers for the purpose of cultivating
120 marijuana at home for personal use.

121 "Marijuana establishment" means a marijuana cultivation facility, a marijuana testing facility, a

marijuana manufacturing facility, a marijuana wholesaler, or a retail marijuana store.

"Marijuana manufacturing facility" means a facility licensed under this subtitle to manufacture, label, and package retail marijuana and retail marijuana products; to purchase or take possession of retail marijuana from a marijuana cultivation facility or another marijuana manufacturing facility; and to transfer possession of and sell retail marijuana and retail marijuana products to marijuana wholesalers, retail marijuana stores, or other marijuana manufacturing facilities.

"Marijuana paraphernalia" means all equipment, products, and materials of any kind that are either designed for use or are intended for use in planting, propagating, cultivating, growing, harvesting, manufacturing, compounding, converting, producing, processing, preparing, strength testing, analyzing, packaging, repackaging, storing, containing, concealing, ingesting, inhaling, or otherwise introducing into the human body marijuana.

"Marijuana products" means (i) products that are composed of marijuana and other ingredients and are intended for use or consumption, ointments, and tinctures or (ii) marijuana concentrate.

"Marijuana testing facility" means a facility licensed under this subtitle to develop, research, or test marijuana, marijuana products, and other substances.

"Marijuana wholesaler" means a facility licensed under this subtitle to purchase or take possession of retail marijuana, retail marijuana products, immature marijuana plants, and marijuana seeds from a marijuana cultivation facility, a marijuana manufacturing facility, or another marijuana wholesaler and to transfer possession and sell or resell retail marijuana, retail marijuana products, immature marijuana plants, and marijuana seeds to a marijuana cultivation facility, marijuana manufacturing facility, retail marijuana store, or another marijuana wholesaler.

"Non-retail marijuana" means marijuana that is not cultivated, manufactured, or sold by a licensed marijuana establishment.

"Non-retail marijuana products" means marijuana products that are not manufactured and sold by a licensed marijuana establishment.

"Place or premises" means the real estate, together with any buildings or other improvements thereon, designated in the application for a license as the place at which the cultivation, manufacture, sale, or testing of retail marijuana or retail marijuana products shall be performed, except that portion of any such building or other improvement actually and exclusively used as a private residence.

"Public place" means any place, building, or conveyance to which the public has, or is permitted to have, access, including restaurants, soda fountains, hotel dining areas, lobbies and corridors of hotels, and any park, place of public resort or amusement, highway, street, lane, or sidewalk adjoining any highway, street, or lane.

"Residence" means any building or part of a building or structure where a person resides, but does not include any part of a building that is not actually and exclusively used as a private residence, nor any part of a hotel or club other than a private guest room thereof.

"Retail marijuana" means marijuana that is cultivated, manufactured, or sold by a licensed marijuana establishment.

"Retail marijuana products" means marijuana products that are manufactured and sold by a licensed marijuana establishment.

"Retail marijuana store" means a facility licensed under this subtitle to purchase or take possession of retail marijuana, retail marijuana products, immature marijuana plants, or marijuana seeds from a marijuana cultivation facility, marijuana manufacturing facility, or marijuana wholesaler and to sell retail marijuana, retail marijuana products, immature marijuana plants, or marijuana seeds to consumers.

"Sale" and "sell" includes soliciting or receiving an order for; keeping, offering, or exposing for sale; peddling, exchanging, or bartering; or delivering otherwise than gratuitously, by any means, retail marijuana or retail marijuana products.

"Special agent" means an employee of the Virginia Cannabis Control Authority whom the Board has designated as a law-enforcement officer pursuant to this subtitle.

"Testing" or "test" means the research and analysis of marijuana, marijuana products, or other substances for contaminants, safety, or potency. "Testing" or "test" does not include cultivation or manufacturing.

"Tetrahydrocannabinol" or "THC" means any naturally occurring or synthetic tetrahydrocannabinol, including its salts, isomers, or salts of isomers.

"Total tetrahydrocannabinol concentration" means the total available tetrahydrocannabinol derived from the molar sum of tetrahydrocannabinol and tetrahydrocannabinol acid.

§ 4.1-606. Regulations of the Board.

A. The Board may promulgate reasonable regulations, not inconsistent with this subtitle or the general laws of the Commonwealth, that it deems necessary to carry out the provisions of this subtitle and to prevent the illegal cultivation, manufacture, sale, and testing of marijuana and marijuana products. The Board may amend or repeal such regulations. Such regulations shall be promulgated, amended, or

183 repealed in accordance with the Administrative Process Act (§ 2.2-4000 et seq.) and shall have the effect
184 of law.

185 B. The Board shall promulgate regulations that:

186 1. Govern the outdoor cultivation of marijuana by a marijuana cultivation facility licensee, including
187 security requirements to include lighting, physical security, and alarm requirements, provided that such
188 requirements do not prohibit the cultivation of marijuana outdoors or in a greenhouse;

189 2. Establish requirements for securely transporting marijuana between marijuana establishments;

190 3. Establish sanitary standards for retail marijuana product preparation;

191 4. Establish a testing program for retail marijuana and retail marijuana products pursuant to Chapter
192 14 (§ 4.1-1400 et seq.);

193 5. Establish an application process for licensure as a marijuana establishment pursuant to this subtitle
194 in a way that, when possible, prevents disparate impacts on historically disadvantaged communities;

195 6. Establish requirements for health and safety warning labels to be placed on retail marijuana and
196 retail marijuana products to be sold or offered for sale by a licensee to a consumer in accordance with
197 the provisions of this subtitle;

198 7. Establish a maximum tetrahydrocannabinol level for retail marijuana products, which shall not
199 exceed (i) five milligrams per serving for edible marijuana products and where practicable an equivalent
200 amount for other marijuana products or (ii) 50 milligrams per package for edible marijuana products and
201 where practicable an equivalent amount for other marijuana products. Such regulations may include
202 other product and dispensing limitations on tetrahydrocannabinol;

203 8. Establish requirements for the form, content, and retention of all records and accounts by all
204 licensees;

205 9. Provide alternative methods for licensees to maintain and store business records that are subject to
206 Board inspection, including methods for Board-approved electronic and offsite storage;

207 10. Establish (i) criteria by which to evaluate new licensees based on the density of retail marijuana
208 stores in the community and (ii) metrics that have similarly shown an association with negative
209 community-level health outcomes or health disparities. In promulgating such regulations, the Board shall
210 coordinate with the Cannabis Public Health Advisory Council established pursuant to § 4.1-603;

211 11. Require retail licensees to file an appeal from any hearing decision rendered by a hearing officer
212 within 30 days of the date the notice of the decision is sent. The notice shall be sent to the licensee at
213 the address on record with the Board by certified mail, return receipt requested, and by regular mail;

214 12. Prescribe the schedule of proration for refunded license fees to licensees who qualify pursuant to
215 subsection C of § 4.1-1002;

216 13. Establish criteria by which to evaluate social equity license applicants, which shall be an
217 applicant who has lived or been domiciled for at least 12 months in the Commonwealth and is either (i)
218 an applicant with at least 66 percent ownership by a person or persons who have been convicted of or
219 adjudicated delinquent for any misdemeanor violation of § 18.2-248.1, former § 18.2-250.1, or subsection
220 A of § 18.2-265.3 as it relates to marijuana; (ii) an applicant with at least 66 percent ownership by a
221 person or persons who is the parent, child, sibling, or spouse of a person who has been convicted of or
222 adjudicated delinquent for any misdemeanor violation of § 18.2-248.1, former § 18.2-250.1, or subsection
223 A of § 18.2-265.3 as it relates to marijuana; (iii) an applicant with at least 66 percent ownership by a
224 person or persons who have resided for at least three of the past five years in a jurisdiction that is
225 determined by the Board after utilizing census tract data made available by the United States Census
226 Bureau to have been disproportionately policed for marijuana crimes; (iv) an applicant with at least 66
227 percent ownership by a person or persons who have resided for at least three of the last five years in a
228 jurisdiction determined by the Board after utilizing census tract data made available by the United States
229 Census Bureau to be economically distressed; or (v) an applicant with at least 66 percent ownership by
230 a person or persons who graduated from a historically black college or university located in the
231 Commonwealth;

232 14. For the purposes of establishing criteria by which to evaluate social equity license applicants,
233 establish standards by which to determine (i) which jurisdictions have been disproportionately policed
234 for marijuana crimes and (ii) which jurisdictions are economically distressed;

235 15. Establish standards and requirements for (i) any preference in the licensing process for qualified
236 social equity applicants, (ii) what percentage of application or license fees are waived for a qualified
237 social equity applicant, and (iii) a low-interest business loan program for qualified social equity
238 applicants;

239 16. Establish guidelines, in addition to requirements set forth in this subtitle, for the personal
240 cultivation of marijuana that promote personal and public safety, including child protection, and
241 discourage personal cultivation practices that create a nuisance, including a nuisance caused by odor;

242 17. Establish reasonable time, place, and manner restrictions on outdoor advertising of retail
243 marijuana or retail marijuana products, not inconsistent with the provisions of this chapter, so that such
244 advertising displaces the illicit market and notifies the public of the location of marijuana establishments.

Such regulations shall be promulgated in accordance with § 4.1-1404;

18. Establish restrictions on the number of licenses that a person may be granted to operate a marijuana establishment in single locality or region; ~~and~~

19. Establish restrictions on pharmaceutical processors and industrial hemp processors that have been granted a license in more than one license category pursuant to subsection C of § 4.1-805 that ensure all licensees have an equal and meaningful opportunity to participate in the market. Such regulations may limit the amount of products cultivated or manufactured by the pharmaceutical processor or industrial hemp processor that such processor may offer for sale in its retail marijuana stores; *and*

20. *Prohibit the production and sale of retail marijuana and retail marijuana products that depict or are in the shape of a human, animal, vehicle, or fruit.*

C. The Board may promulgate regulations that:

1. Limit the number of licenses issued by type or class to operate a marijuana establishment; however, the number of licenses issued shall not exceed the following limits:

- a. Retail marijuana stores, 400;
- b. Marijuana wholesalers, 25;
- c. Marijuana manufacturing facilities, 60; and
- d. Marijuana cultivation facilities, 450.

In determining the number of licenses issued pursuant to this subdivision, the Board shall not consider any license granted pursuant to subsection C of § 4.1-805 to (i) a pharmaceutical processor that has been issued a permit by the Board of Pharmacy pursuant to Article 4.2 (§ 54.1-3442.5 et seq.) of the Drug Control Act or (ii) an industrial hemp processor registered with the Commissioner of Agriculture and Consumer Services pursuant to Chapter 41.1 (§ 3.2-4112 et seq.) of Title 3.2.

2. Prescribe any requirements deemed appropriate for the administration of taxes under §§ 4.1-1003 and 4.1-1004, including method of filing a return, information required on a return, and form of payment.

3. Limit the allowable square footage of a retail marijuana store, which shall not exceed 1,500 square feet.

4. Allow certain persons to be granted or have interest in a license in more than one of the following license categories: marijuana cultivation facility license, marijuana manufacturing facility license, marijuana wholesaler license, or retail marijuana store license. Such regulations shall be drawn narrowly to limit vertical integration to small businesses and ensure that all licensees have an equal and meaningful opportunity to participate in the market.

D. Board regulations shall be uniform in their application, except those relating to hours of sale for licensees.

E. Courts shall take judicial notice of Board regulations.

F. The Board shall consult with the Cannabis Public Health Advisory Council in promulgating any regulations relating to public health, including regulations promulgated pursuant to subdivision B 3, 4, 6, 7, 10, or 16, and shall not promulgate any such regulation that has not been approved by a majority of the members of the Cannabis Public Health Advisory Council.

G. With regard to regulations governing licensees that have been issued a permit by the Board of Pharmacy to operate as a pharmaceutical processor or cannabis dispensing facility pursuant to Article 4.2 (§ 54.1-3442.5 et seq.) of the Drug Control Act, the Board shall make reasonable efforts (i) to align such regulations with any applicable regulations promulgated by the Board of Pharmacy that establish health, safety, and security requirements for pharmaceutical processors and cannabis dispensing facilities and (ii) to deem in compliance with applicable regulations promulgated pursuant to this subtitle such pharmaceutical processors and cannabis dispensing facilities that have been found to be in compliance with regulations promulgated by the Board of Pharmacy that mirror or are more extensive in scope than similar regulations promulgated pursuant to this subtitle.

H. The Board's power to regulate shall be broadly construed.

§ 9.1-1101. Powers and duties of the Department.

A. It shall be the responsibility of the Department to provide forensic laboratory services upon request of the Superintendent of State Police; the Chief Medical Examiner, the Assistant Chief Medical Examiners, and local medical examiners; any attorney for the Commonwealth; any chief of police, sheriff, or sergeant responsible for law enforcement in the jurisdiction served by him; any local fire department; the head of any private police department that has been designated as a criminal justice agency by the Department of Criminal Justice Services as defined by § 9.1-101; or any state agency in any criminal matter. The Department shall provide such services to any federal investigatory agency within available resources.

B. The Department shall:

1. Provide forensic laboratory services to all law-enforcement agencies throughout the Commonwealth and provide laboratory services, research, and scientific investigations for agencies of

the Commonwealth as needed;

2. Establish and maintain a DNA testing program in accordance with Article 1.1 (§ 19.2-310.2 et seq.) of Chapter 18 of Title 19.2 to determine identification characteristics specific to an individual; and

3. Test the accuracy of equipment used to test the blood alcohol content of breath at least once every six months. Only equipment found to be accurate shall be used to test the blood alcohol content of breath.

C. The Department shall have the power and duty to:

1. Receive, administer, and expend all funds and other assistance available for carrying out the purposes of this chapter;

2. Make and enter into all contracts and agreements necessary or incidental to the performance of its duties and execution of its powers under this chapter including, but not limited to, contracts with the United States, units of general local government or combinations thereof in Virginia or other states, and with agencies and departments of the Commonwealth; and

3. Perform such other acts as may be necessary or convenient for the effective performance of its duties; and

4. Determine the proper methods for detecting the concentration of tetrahydrocannabinol (THC) in substances for the purposes of Chapter 11 (§ 4.1-1100 et seq.) of Title 4.1, Chapter 7 (§ 18.2-247 et seq.) of Title 18.2, and §§ 54.1-3401 and 54.1-3446. The testing methodology shall use post-decarboxylation testing or another equivalent method and shall consider the potential conversion of tetrahydrocannabinol acid (THC-A) into THC. The test result shall include the total available THC derived from the sum of the THC and THC-A content.

D. The Director may appoint and employ a deputy director and such other personnel as are needed to carry out the duties and responsibilities conferred by this chapter.

§ 18.2-247. Use of terms "controlled substances," "marijuana," "Schedules I, II, III, IV, V, and VI," "imitation controlled substance" and "counterfeit controlled substance" in Title 18.2.

A. ~~Wherever the terms~~ As used in this title, "controlled substances" substance" and "Schedules I, II, III, IV, V, and VI" ~~are used in Title 18.2; such terms refer to mean the same as those terms as they are~~ used or defined in the Drug Control Act (§ 54.1-3400 et seq.).

B. ~~The term~~ When used in this article, "imitation controlled substance" ~~when used in this article~~ means (i) a counterfeit controlled substance or (ii) a pill, capsule, tablet, or substance in any form whatsoever ~~which that~~ is not a controlled substance subject to abuse; and:

1. Which by overall dosage unit appearance, including color, shape, size, marking, and packaging or by representations made, would cause the likelihood that such a pill, capsule, tablet, or substance in any other form whatsoever will be mistaken for a controlled substance unless such substance was introduced into commerce prior to the initial introduction into commerce of the controlled substance ~~which that~~ it is alleged to imitate; or

2. Which by express or implied representations purports to act like a controlled substance as a stimulant or depressant of the central nervous system and which is not commonly used or recognized for use in that particular formulation for any purpose other than for such stimulant or depressant effect, unless marketed, promoted, or sold as permitted by the U.S. Food and Drug Administration.

C. In determining whether a pill, capsule, tablet, or substance in any other form whatsoever, is an "imitation controlled substance," there shall be considered, in addition to all other relevant factors, comparisons with accepted methods of marketing for legitimate nonprescription drugs for medicinal purposes rather than for drug abuse or any similar nonmedicinal use, including consideration of the packaging of the drug and its appearance in overall finished dosage form, promotional materials or representations, oral or written, concerning the drug, and the methods of distribution of the drug and where and how it is sold to the public.

D. ~~The term "marijuana" when~~ As used in this article:

"Counterfeit controlled substance" means a controlled substance that, without authorization, bears, is packaged in a container or wrapper that bears, or is otherwise labeled to bear the trademark, trade name, or other identifying mark, imprint, or device or any likeness thereof of a drug manufacturer, processor, packer, or distributor other than the manufacturer, processor, packer, or distributor that did in fact so manufacture, process, pack, or distribute such drug.

"Marijuana" means (i) any part of a plant of the genus Cannabis, whether growing or not, its seeds or resin; and every compound, manufacture, salt, derivative, mixture, or preparation of such plant, its seeds, its resin, or any extract containing one or more cannabinoids or (ii) any substance containing a total tetrahydrocannabinol concentration that exceeds 0.3 percent, including a hemp product, as defined in § 3.2-4112, or an industrial hemp extract, as defined in § 3.2-5145.1. "Marijuana" does not include (a) the mature stalks of such plant, fiber produced from such stalk, oil or cake made from the seed of such plant, unless such stalks, fiber, oil or cake is combined with other parts of plants of the genus Cannabis. ~~Marijuana does not include (i);~~ (b) industrial hemp, as defined in § 3.2-4112, that is possessed by a person registered pursuant to subsection A of § 3.2-4115 or his agent; ~~(ii)~~ (c) industrial hemp, as

defined in § 3.2-4112, that is possessed by a person who holds a hemp producer license issued by the U.S. Department of Agriculture pursuant to 7 C.F.R. Part 990; ~~or (iii)~~ (d) a hemp product, as defined in § 3.2-4112, containing a tetrahydrocannabinol concentration of no greater than 0.3 percent that is derived from industrial hemp, as defined in § 3.2-4112, that is grown, dealt, or processed in compliance with state or federal law; (e) *an industrial hemp extract, as defined in § 3.2-5145.1, containing a tetrahydrocannabinol concentration of no greater than 0.3 percent that is derived from industrial hemp, as defined in § 3.2-4112, grown, dealt, or processed in compliance with state or federal law; or* (f) any drug product containing tetrahydrocannabinol that is approved for marketing by the U.S. Food and Drug Administration and scheduled in the Drug Control Act (§ 54.1-3400 et seq.) by the Board of Pharmacy pursuant to § 54.1-3443.

"Tetrahydrocannabinol" or "THC" means any naturally occurring or synthetic tetrahydrocannabinol, including its salts, isomers, or salts of isomers.

"Total tetrahydrocannabinol concentration" means the total available tetrahydrocannabinol derived from the molar sum of tetrahydrocannabinol and tetrahydrocannabinol acid.

E. The term "counterfeit controlled substance" means a controlled substance that, without authorization, bears, is packaged in a container or wrapper that bears, or is otherwise labeled to bear, the trademark, trade name, or other identifying mark, imprint or device or any likeness thereof, of a drug manufacturer, processor, packer, or distributor other than the manufacturer, processor, packer, or distributor who did in fact so manufacture, process, pack or distribute such drug.

F. The Department of Forensic Science shall determine the proper methods for detecting the concentration of ~~delta-9-tetrahydrocannabinol (THC)~~ tetrahydrocannabinol in substances for the purposes of this title, Chapter 11 (§ 4.1-1100 et seq.) of Title 4.1, and §§ § 54.1-3401 and 54.1-3446. The testing methodology shall use post-decarboxylation testing or other equivalent method and shall consider the potential conversion of ~~delta-9-tetrahydrocannabinol~~ tetrahydrocannabinolic acid (THC-A) into THC. The test result shall include the total available THC derived from the sum of the THC and THC-A content.

§ 18.2-251.1. Possession or distribution of marijuana for medical purposes permitted.

A. No person shall be prosecuted under § 18.2-250 or § 18.2-250.1 for the possession of marijuana ~~or tetrahydrocannabinol~~ when that possession occurs pursuant to a valid prescription issued by a medical doctor in the course of his professional practice for treatment of cancer or glaucoma.

B. No medical doctor shall be prosecuted under § 18.2-248 or § 18.2-248.1 for dispensing or distributing marijuana ~~or tetrahydrocannabinol~~ for medical purposes when such action occurs in the course of his professional practice for treatment of cancer or glaucoma.

C. No pharmacist shall be prosecuted under §§ 18.2-248 to 18.2-248.1 for dispensing or distributing marijuana ~~or tetrahydrocannabinol~~ to any person who holds a valid prescription of a medical doctor for such substance issued in the course of such doctor's professional practice for treatment of cancer or glaucoma.

§ 19.2-188.1. Testimony regarding identification of controlled substances.

A. In any preliminary hearing on a violation of Chapter 11 (§ 4.1-1100 et seq.) of Title 4.1, Article 1 (§ 18.2-247 et seq.) of Chapter 7 of Title 18.2, or subdivision 6 of § 53.1-203, any law-enforcement officer shall be permitted to testify as to the results of field tests that have been approved by the Department of Forensic Science pursuant to regulations adopted in accordance with the Administrative Process Act (§ 2.2-4000 et seq.), regarding whether or not any substance the identity of which is at issue in such hearing is a controlled substance, imitation controlled substance, or marijuana, as defined in § 4.1-600 or 18.2-247.

B. In any trial for a violation of § 4.1-1105.1, any law-enforcement officer shall be permitted to testify as to the results of any marijuana field test approved as accurate and reliable by the Department of Forensic Science pursuant to regulations adopted in accordance with the Administrative Process Act (§ 2.2-4000 et seq.), regarding whether or not any plant material, the identity of which is at issue, is marijuana provided the defendant has been given written notice of his right to request a full chemical analysis. Such notice shall be on a form approved by the Supreme Court and shall be provided to the defendant prior to trial.

In any case in which the person accused of a violation of § 4.1-1105.1, or the attorney of record for the accused, desires a full chemical analysis of the alleged plant material, he may, by motion prior to trial before the court in which the charge is pending, request such a chemical analysis. Upon such motion, the court shall order that the analysis be performed by the Department of Forensic Science in accordance with the provisions of § 18.2-247 and shall prescribe in its order the method of custody, transfer, and return of evidence submitted for chemical analysis.

§ 54.1-3401. Definitions.

As used in this chapter, unless the context requires a different meaning:

"Administer" means the direct application of a controlled substance, whether by injection, inhalation, ingestion, or any other means, to the body of a patient or research subject by (i) a practitioner or by his

429 authorized agent and under his direction or (ii) the patient or research subject at the direction and in the
430 presence of the practitioner.

431 "Advertisement" means all representations disseminated in any manner or by any means, other than
432 by labeling, for the purpose of inducing, or which are likely to induce, directly or indirectly, the
433 purchase of drugs or devices.

434 "Agent" means an authorized person who acts on behalf of or at the direction of a manufacturer,
435 distributor, or dispenser. It does not include a common or contract carrier, public warehouseman, or
436 employee of the carrier or warehouseman.

437 "Anabolic steroid" means any drug or hormonal substance, chemically and pharmacologically related
438 to testosterone, other than estrogens, progestins, corticosteroids, and dehydroepiandrosterone.

439 "Animal" means any nonhuman animate being endowed with the power of voluntary action.

440 "Automated drug dispensing system" means a mechanical or electronic system that performs
441 operations or activities, other than compounding or administration, relating to pharmacy services,
442 including the storage, dispensing, or distribution of drugs and the collection, control, and maintenance of
443 all transaction information, to provide security and accountability for such drugs.

444 "Biological product" means a virus, therapeutic serum, toxin, antitoxin, vaccine, blood, blood
445 component or derivative, allergenic product, protein other than a chemically synthesized polypeptide, or
446 analogous product, or arsphenamine or any derivative of arsphenamine or any other trivalent organic
447 arsenic compound, applicable to the prevention, treatment, or cure of a disease or condition of human
448 beings.

449 "Biosimilar" means a biological product that is highly similar to a specific reference biological
450 product, notwithstanding minor differences in clinically inactive compounds, such that there are no
451 clinically meaningful differences between the reference biological product and the biological product that
452 has been licensed as a biosimilar pursuant to 42 U.S.C. § 262(k) in terms of safety, purity, and potency
453 of the product.

454 "Board" means the Board of Pharmacy.

455 "Bulk drug substance" means any substance that is represented for use, and that, when used in the
456 compounding, manufacturing, processing, or packaging of a drug, becomes an active ingredient or a
457 finished dosage form of the drug; however, "bulk drug substance" shall not include intermediates that
458 are used in the synthesis of such substances.

459 "Change of ownership" of an existing entity permitted, registered, or licensed by the Board means (i)
460 the sale or transfer of all or substantially all of the assets of the entity or of any corporation that owns
461 or controls the entity; (ii) the creation of a partnership by a sole proprietor, the dissolution of a
462 partnership, or change in partnership composition; (iii) the acquisition or disposal of 50 percent or more
463 of the outstanding shares of voting stock of a corporation owning the entity or of the parent corporation
464 of a wholly owned subsidiary owning the entity, except that this shall not apply to any corporation the
465 voting stock of which is actively traded on any securities exchange or in any over-the-counter market;
466 (iv) the merger of a corporation owning the entity or of the parent corporation of a wholly-owned
467 subsidiary owning the entity with another business or corporation; or (v) the expiration or forfeiture of a
468 corporation's charter.

469 "Co-licensed partner" means a person who, with at least one other person, has the right to engage in
470 the manufacturing or marketing of a prescription drug, consistent with state and federal law.

471 "Compounding" means the combining of two or more ingredients to fabricate such ingredients into a
472 single preparation and includes the mixing, assembling, packaging, or labeling of a drug or device (i) by
473 a pharmacist, or within a permitted pharmacy, pursuant to a valid prescription issued for a medicinal or
474 therapeutic purpose in the context of a bona fide practitioner-patient-pharmacist relationship, or in
475 expectation of receiving a valid prescription based on observed historical patterns of prescribing and
476 dispensing; (ii) by a practitioner of medicine, osteopathy, podiatry, dentistry, or veterinary medicine as
477 an incident to his administering or dispensing, if authorized to dispense, a controlled substance in the
478 course of his professional practice; or (iii) for the purpose of, or as incident to, research, teaching, or
479 chemical analysis and not for sale or for dispensing. The mixing, diluting, or reconstituting of a
480 manufacturer's product drugs for the purpose of administration to a patient, when performed by a
481 practitioner of medicine or osteopathy licensed under Chapter 29 (§ 54.1-2900 et seq.), a person
482 supervised by such practitioner pursuant to subdivision A 6 or 19 of § 54.1-2901, or a person supervised
483 by such practitioner or a licensed nurse practitioner or physician assistant pursuant to subdivision A 4 of
484 § 54.1-2901 shall not be considered compounding.

485 "Controlled substance" means a drug, substance, or immediate precursor in Schedules I through VI of
486 this chapter. The term shall not include distilled spirits, wine, malt beverages, or tobacco as those terms
487 are defined or used in Title 3.2 or Title 4.1. The term "controlled substance" includes a controlled
488 substance analog that has been placed into Schedule I or II by the Board pursuant to the regulatory
489 authority in subsection D of § 54.1-3443.

490 "Controlled substance analog" means a substance the chemical structure of which is substantially

similar to the chemical structure of a controlled substance in Schedule I or II and either (i) which has a stimulant, depressant, or hallucinogenic effect on the central nervous system that is substantially similar to or greater than the stimulant, depressant, or hallucinogenic effect on the central nervous system of a controlled substance in Schedule I or II or (ii) with respect to a particular person, which such person represents or intends to have a stimulant, depressant, or hallucinogenic effect on the central nervous system that is substantially similar to or greater than the stimulant, depressant, or hallucinogenic effect on the central nervous system of a controlled substance in Schedule I or II. "Controlled substance analog" does not include (a) any substance for which there is an approved new drug application as defined under § 505 of the federal Food, Drug, and Cosmetic Act (21 U.S.C. § 355) or that is generally recognized as safe and effective pursuant to §§ 501, 502, and 503 of the federal Food, Drug, and Cosmetic Act (21 U.S.C. §§ 351, 352, and 353) and 21 C.F.R. Part 330; (b) with respect to a particular person, any substance for which an exemption is in effect for investigational use for that person under § 505 of the federal Food, Drug, and Cosmetic Act to the extent that the conduct with respect to that substance is pursuant to such exemption; or (c) any substance to the extent not intended for human consumption before such an exemption takes effect with respect to that substance.

"DEA" means the Drug Enforcement Administration, U.S. Department of Justice, or its successor agency.

"Deliver" or "delivery" means the actual, constructive, or attempted transfer of any item regulated by this chapter, whether or not there exists an agency relationship, including delivery of a Schedule VI prescription device to an ultimate user or consumer on behalf of a medical equipment supplier by a manufacturer, nonresident manufacturer, wholesale distributor, nonresident wholesale distributor, warehouse, nonresident warehouse, third-party logistics provider, or nonresident third-party logistics provider at the direction of a medical equipment supplier in accordance with § 54.1-3415.1.

"Device" means instruments, apparatus, and contrivances, including their components, parts, and accessories, intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease in man or animals or to affect the structure or any function of the body of man or animals.

"Dialysis care technician" or "dialysis patient care technician" means an individual who is certified by an organization approved by the Board of Health Professions pursuant to Chapter 27.01 (§ 54.1-2729.1 et seq.) and who, under the supervision of a licensed physician, nurse practitioner, physician assistant, or a registered nurse, assists in the care of patients undergoing renal dialysis treatments in a Medicare-certified renal dialysis facility.

"Dialysis solution" means either the commercially available, unopened, sterile solutions whose purpose is to be instilled into the peritoneal cavity during the medical procedure known as peritoneal dialysis, or commercially available solutions whose purpose is to be used in the performance of hemodialysis not to include any solutions administered to the patient intravenously.

"Dispense" means to deliver a drug to an ultimate user or research subject by or pursuant to the lawful order of a practitioner, including the prescribing and administering, packaging, labeling, or compounding necessary to prepare the substance for that delivery. However, dispensing shall not include the transportation of drugs mixed, diluted, or reconstituted in accordance with this chapter to other sites operated by such practitioner or that practitioner's medical practice for the purpose of administration of such drugs to patients of the practitioner or that practitioner's medical practice at such other sites. For practitioners of medicine or osteopathy, "dispense" shall only include the provision of drugs by a practitioner to patients to take with them away from the practitioner's place of practice.

"Dispenser" means a practitioner who dispenses.

"Distribute" means to deliver other than by administering or dispensing a controlled substance.

"Distributor" means a person who distributes.

"Drug" means (i) articles or substances recognized in the official United States Pharmacopoeia National Formulary or official Homeopathic Pharmacopoeia of the United States, or any supplement to any of them; (ii) articles or substances intended for use in the diagnosis, cure, mitigation, treatment, or prevention of disease in man or animals; (iii) articles or substances, other than food, intended to affect the structure or any function of the body of man or animals; (iv) articles or substances intended for use as a component of any article specified in clause (i), (ii), or (iii); or (v) a biological product. "Drug" does not include devices or their components, parts, or accessories.

"Drug product" means a specific drug in dosage form from a known source of manufacture, whether by brand or therapeutically equivalent drug product name.

"Electronic prescription" means a written prescription that is generated on an electronic application and is transmitted to a pharmacy as an electronic data file; Schedule II through V prescriptions shall be transmitted in accordance with 21 C.F.R. Part 1300.

"Facsimile (FAX) prescription" means a written prescription or order that is transmitted by an electronic device over telephone lines that sends the exact image to the receiving pharmacy in hard copy form.

552 "FDA" means the U.S. Food and Drug Administration.

553 "Immediate precursor" means a substance which the Board of Pharmacy has found to be and by
554 regulation designates as being the principal compound commonly used or produced primarily for use,
555 and which is an immediate chemical intermediary used or likely to be used in the manufacture of a
556 controlled substance, the control of which is necessary to prevent, curtail, or limit manufacture.

557 "Interchangeable" means a biosimilar that meets safety standards for determining interchangeability
558 pursuant to 42 U.S.C. § 262(k)(4).

559 "Label" means a display of written, printed, or graphic matter upon the immediate container of any
560 article. A requirement made by or under authority of this chapter that any word, statement, or other
561 information appear on the label shall not be considered to be complied with unless such word,
562 statement, or other information also appears on the outside container or wrapper, if any, of the retail
563 package of such article or is easily legible through the outside container or wrapper.

564 "Labeling" means all labels and other written, printed, or graphic matter on an article or any of its
565 containers or wrappers, or accompanying such article.

566 "Manufacture" means the production, preparation, propagation, conversion, or processing of any item
567 regulated by this chapter, either directly or indirectly by extraction from substances of natural origin, or
568 independently by means of chemical synthesis, or by a combination of extraction and chemical
569 synthesis, and includes any packaging or repackaging of the substance or labeling or relabeling of its
570 container. This term does not include compounding.

571 "Manufacturer" means every person who manufactures, a manufacturer's co-licensed partner, or a
572 repackager.

573 "Marijuana" means (i) any part of a plant of the genus *Cannabis* whether growing or not, its seeds,
574 or its resin; and every compound, manufacture, salt, derivative, mixture, or preparation of such plant, its
575 seeds, its resin, or any extract containing one or more cannabinoids or (ii) *any substance containing a*
576 *total tetrahydrocannabinol concentration that exceeds 0.3 percent, including a hemp product, as defined*
577 *in § 3.2-4112, or an industrial hemp extract, as defined in § 3.2-5145.1. Marijuana does not include (a)*
578 *the mature stalks of such plant, fiber produced from such stalk, or oil or cake made from the seeds of*
579 *such plant, unless such stalks, fiber, oil, or cake is combined with other parts of plants of the genus*
580 *Cannabis;* ~~Marijuana does not include (i);~~ (b) industrial hemp, as defined in § 3.2-4112, that is possessed
581 by a person registered pursuant to subsection A of § 3.2-4115 or his agent, ~~(ii);~~ (c) industrial hemp, as
582 defined in § 3.2-4112, that is possessed by a person who holds a hemp producer license issued by the
583 U.S. Department of Agriculture pursuant to 7 C.F.R. Part 990, ~~or (iii);~~ (d) a hemp product, as defined in
584 § 3.2-4112, containing a tetrahydrocannabinol concentration of no greater than 0.3 percent that is derived
585 from industrial hemp, as defined in § 3.2-4112, that is grown, dealt, or processed in compliance with
586 state or federal law; (e) *an industrial hemp extract, as defined in § 3.2-5145.1, containing a*
587 *tetrahydrocannabinol concentration of no greater than 0.3 percent that is derived from industrial hemp,*
588 *as defined in § 3.2-4112, grown, dealt, or processed in compliance with state or federal law; or (f) any*
589 *drug product containing tetrahydrocannabinol that is approved for marketing by the U.S. Food and*
590 *Drug Administration and scheduled in the Drug Control Act (§ 54.1-3400 et seq.) by the Board of*
591 *Pharmacy pursuant to § 54.1-3443.*

592 "Medical equipment supplier" means any person, as defined in § 1-230, engaged in the delivery to
593 the ultimate consumer, pursuant to the lawful order of a practitioner, of hypodermic syringes and
594 needles, medicinal oxygen, Schedule VI controlled devices, those Schedule VI controlled substances with
595 no medicinal properties that are used for the operation and cleaning of medical equipment, solutions for
596 peritoneal dialysis, and sterile water or saline for irrigation.

597 "Narcotic drug" means any of the following, whether produced directly or indirectly by extraction
598 from substances of vegetable origin, or independently by means of chemical synthesis, or by a
599 combination of extraction and chemical synthesis: (i) opium, opiates, and any salt, compound, derivative,
600 or preparation of opium or opiates; (ii) any salt, compound, isomer, derivative, or preparation thereof
601 which is chemically equivalent or identical with any of the substances referred to in clause (i), but not
602 including the isoquinoline alkaloids of opium; (iii) opium poppy and poppy straw; (iv) coca leaves and
603 any salt, compound, derivative, or preparation of coca leaves, and any salt, compound, isomer,
604 derivative, or preparation thereof which is chemically equivalent or identical with any of these
605 substances, but not including decocainized coca leaves or extraction of coca leaves which do not contain
606 cocaine or ecgonine.

607 "New drug" means (i) any drug, except a new animal drug or an animal feed bearing or containing a
608 new animal drug, the composition of which is such that such drug is not generally recognized, among
609 experts qualified by scientific training and experience to evaluate the safety and effectiveness of drugs,
610 as safe and effective for use under the conditions prescribed, recommended, or suggested in the labeling,
611 except that such a drug not so recognized shall not be deemed to be a "new drug" if at any time prior
612 to the enactment of this chapter it was subject to the Food and Drugs Act of June 30, 1906, as
613 amended, and if at such time its labeling contained the same representations concerning the conditions

of its use, or (ii) any drug, except a new animal drug or an animal feed bearing or containing a new animal drug, the composition of which is such that such drug, as a result of investigations to determine its safety and effectiveness for use under such conditions, has become so recognized, but which has not, otherwise than in such investigations, been used to a material extent or for a material time under such conditions.

"Nuclear medicine technologist" means an individual who holds a current certification with the American Registry of Radiological Technologists or the Nuclear Medicine Technology Certification Board.

"Official compendium" means the official United States Pharmacopoeia National Formulary, official Homeopathic Pharmacopoeia of the United States, or any supplement to any of them.

"Official written order" means an order written on a form provided for that purpose by the U.S. Drug Enforcement Administration, under any laws of the United States making provision therefor, if such order forms are authorized and required by federal law, and if no such order form is provided then on an official form provided for that purpose by the Board of Pharmacy.

"Opiate" means any substance having an addiction-forming or addiction-sustaining liability similar to morphine or being capable of conversion into a drug having such addiction-forming or addiction-sustaining liability. It does not include, unless specifically designated as controlled under Article 4 (§ 54.1-3437 et seq.), the dextrorotatory isomer of 3-methoxy-n-methylmorphinan and its salts (dextromethorphan). It does include its racemic and levorotatory forms.

"Opium poppy" means the plant of the species *Papaver somniferum* L., except the seeds thereof.

"Original package" means the unbroken container or wrapping in which any drug or medicine is enclosed together with label and labeling, put up by or for the manufacturer, wholesaler, or distributor for use in the delivery or display of such article.

"Outsourcing facility" means a facility that is engaged in the compounding of sterile drugs and is currently registered as an outsourcing facility with the U.S. Secretary of Health and Human Services and that complies with all applicable requirements of federal and state law, including the Federal Food, Drug, and Cosmetic Act.

"Person" means both the plural and singular, as the case demands, and includes an individual, partnership, corporation, association, governmental agency, trust, or other institution or entity.

"Pharmacist-in-charge" means the person who, being licensed as a pharmacist, signs the application for a pharmacy permit and assumes full legal responsibility for the operation of the relevant pharmacy in a manner complying with the laws and regulations for the practice of pharmacy and the sale and dispensing of controlled substances; the "pharmacist-in-charge" shall personally supervise the pharmacy and the pharmacy's personnel as required by § 54.1-3432.

"Poppy straw" means all parts, except the seeds, of the opium poppy, after mowing.

"Practitioner" means a physician, dentist, licensed nurse practitioner pursuant to § 54.1-2957.01, licensed physician assistant pursuant to § 54.1-2952.1, pharmacist pursuant to § 54.1-3300, TPA-certified optometrist pursuant to Article 5 (§ 54.1-3222 et seq.) of Chapter 32, veterinarian, scientific investigator, or other person licensed, registered, or otherwise permitted to distribute, dispense, prescribe and administer, or conduct research with respect to a controlled substance in the course of professional practice or research in the Commonwealth.

"Prescriber" means a practitioner who is authorized pursuant to §§ 54.1-3303 and 54.1-3408 to issue a prescription.

"Prescription" means an order for drugs or medical supplies, written or signed or transmitted by word of mouth, telephone, telegraph, or other means of communication to a pharmacist by a duly licensed physician, dentist, veterinarian, or other practitioner authorized by law to prescribe and administer such drugs or medical supplies.

"Prescription drug" means any drug required by federal law or regulation to be dispensed only pursuant to a prescription, including finished dosage forms and active ingredients subject to § 503(b) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. § 353(b)).

"Production" or "produce" includes the manufacture, planting, cultivation, growing, or harvesting of a controlled substance or marijuana.

"Proprietary medicine" means a completely compounded nonprescription drug in its unbroken, original package which does not contain any controlled substance or marijuana as defined in this chapter and is not in itself poisonous, and which is sold, offered, promoted, or advertised directly to the general public by or under the authority of the manufacturer or primary distributor, under a trademark, trade name, or other trade symbol privately owned, and the labeling of which conforms to the requirements of this chapter and applicable federal law. However, this definition shall not include a drug that is only advertised or promoted professionally to licensed practitioners, a narcotic or drug containing a narcotic, a drug that may be dispensed only upon prescription or the label of which bears substantially the statement "Warning — may be habit-forming," or a drug intended for injection.

675 "Radiopharmaceutical" means any drug that exhibits spontaneous disintegration of unstable nuclei
676 with the emission of nuclear particles or photons and includes any non-radioactive reagent kit or
677 radionuclide generator that is intended to be used in the preparation of any such substance, but does not
678 include drugs such as carbon-containing compounds or potassium-containing salts that include trace
679 quantities of naturally occurring radionuclides. The term also includes any biological product that is
680 labeled with a radionuclide or intended solely to be labeled with a radionuclide.

681 "Reference biological product" means the single biological product licensed pursuant to 42 U.S.C.
682 § 262(a) against which a biological product is evaluated in an application submitted to the U.S. Food
683 and Drug Administration for licensure of biological products as biosimilar or interchangeable pursuant to
684 42 U.S.C. § 262(k).

685 "Sale" includes barter, exchange, or gift, or offer therefor, and each such transaction made by any
686 person, whether as an individual, proprietor, agent, servant, or employee.

687 "*Tetrahydrocannabinol*" or "*THC*" means any naturally occurring or synthetic tetrahydrocannabinol,
688 including its salts, isomers, or salts of isomers.

689 "Therapeutically equivalent drug products" means drug products that contain the same active
690 ingredients and are identical in strength or concentration, dosage form, and route of administration and
691 that are classified as being therapeutically equivalent by the U.S. Food and Drug Administration
692 pursuant to the definition of "therapeutically equivalent drug products" set forth in the most recent
693 edition of the Approved Drug Products with Therapeutic Equivalence Evaluations, otherwise known as
694 the "Orange Book."

695 "Third-party logistics provider" means a person that provides or coordinates warehousing of or other
696 logistics services for a drug or device in interstate commerce on behalf of a manufacturer, wholesale
697 distributor, or dispenser of the drug or device but does not take ownership of the product or have
698 responsibility for directing the sale or disposition of the product.

699 "*Total tetrahydrocannabinol concentration*" means the total available tetrahydrocannabinol derived
700 from the molar sum of tetrahydrocannabinol and tetrahydrocannabinol acid.

701 "USP-NF" means the current edition of the United States Pharmacopeia-National Formulary.

702 "Warehouser" means any person, other than a wholesale distributor, manufacturer, or third-party
703 logistics provider, engaged in the business of (i) selling or otherwise distributing prescription drugs or
704 devices to any person who is not the ultimate user or consumer and (ii) delivering Schedule VI
705 prescription devices to the ultimate user or consumer pursuant to § 54.1-3415.1. No person shall be
706 subject to any state or local tax by reason of this definition.

707 "Wholesale distribution" means (i) distribution of prescription drugs to persons other than consumers
708 or patients and (ii) delivery of Schedule VI prescription devices to the ultimate user or consumer
709 pursuant to § 54.1-3415.1, subject to the exemptions set forth in the federal Drug Supply Chain Security
710 Act.

711 "Wholesale distributor" means any person other than a manufacturer, a manufacturer's co-licensed
712 partner, a third-party logistics provider, or a repackager that engages in wholesale distribution.

713 The words "drugs" and "devices" as used in Chapter 33 (§ 54.1-3300 et seq.) and in this chapter
714 shall not include surgical or dental instruments, physical therapy equipment, X-ray apparatus, or glasses
715 or lenses for the eyes.

716 The terms "pharmacist," "pharmacy," and "practice of pharmacy" as used in this chapter shall be
717 defined as provided in Chapter 33 (§ 54.1-3300 et seq.) unless the context requires a different meaning.

718 § 54.1-3408.3. Certification for use of cannabis oil for treatment.

719 A. As used in this section:

720 "Botanical cannabis" means cannabis that is composed wholly of usable cannabis from the same parts
721 of the same chemovar of cannabis plant.

722 "Cannabis oil" means any formulation of processed Cannabis plant extract, which may include oil
723 from industrial hemp extract acquired by a pharmaceutical processor pursuant to § 54.1-3442.6, or a
724 dilution of the resin of the Cannabis plant that contains at least five milligrams of cannabidiol (CBD) or
725 tetrahydrocannabinolic acid (THC-A) and no more than 10 milligrams of ~~delta-9-tetrahydrocannabinol~~
726 *tetrahydrocannabinol* per dose. "Cannabis oil" does not include industrial hemp, as defined in
727 § 3.2-4112, that is grown, dealt, or processed in compliance with state or federal law, unless it has been
728 acquired and formulated with cannabis plant extract by a pharmaceutical processor.

729 "Cannabis product" means a product that is (i) produced by a pharmaceutical processor, registered
730 with the Board, and compliant with testing requirements and (ii) composed of cannabis oil or botanical
731 cannabis.

732 "Designated caregiver facility" means any hospice or hospice facility licensed pursuant to
733 § 32.1-162.3, or home care organization as defined in § 32.1-162.7 that provides pharmaceutical services
734 or home health services, private provider licensed by the Department of Behavioral Health and
735 Developmental Services pursuant to Article 2 (§ 37.2-403 et seq.) of Chapter 4 of Title 37.2, assisted
736 living facility licensed pursuant to § 63.2-1701, or adult day care center licensed pursuant to

§ 63.2-1701.

"Practitioner" means a practitioner of medicine or osteopathy licensed by the Board of Medicine, a physician assistant licensed by the Board of Medicine, or a nurse practitioner jointly licensed by the Board of Medicine and the Board of Nursing.

"Registered agent" means an individual designated by a patient who has been issued a written certification, or, if such patient is a minor or an incapacitated adult as defined in § 18.2-369, designated by such patient's parent or legal guardian, and registered with the Board pursuant to subsection G.

"Usable cannabis" means any cannabis plant material, including seeds, but not (i) resin that has been extracted from any part of the cannabis plant, its seeds, or its resin; (ii) the mature stalks, fiber produced from the stalks, or any other compound, manufacture, salt, or derivative, mixture, or preparation of the mature stalks; or (iii) oil or cake made from the seeds of the plant.

B. A practitioner in the course of his professional practice may issue a written certification for the use of cannabis products for treatment or to alleviate the symptoms of any diagnosed condition or disease determined by the practitioner to benefit from such use. The practitioner shall use his professional judgment to determine the manner and frequency of patient care and evaluation and may employ the use of telemedicine, provided that the use of telemedicine includes the delivery of patient care through real-time interactive audio-visual technology. If a practitioner determines it is consistent with the standard of care to dispense botanical cannabis to a minor, the written certification shall specifically authorize such dispensing. If not specifically included on the initial written certification, authorization for botanical cannabis may be communicated verbally or in writing to the pharmacist at the time of dispensing.

C. The written certification shall be on a form provided by the Office of the Executive Secretary of the Supreme Court developed in consultation with the Board of Medicine. Such written certification shall contain the name, address, and telephone number of the practitioner, the name and address of the patient issued the written certification, the date on which the written certification was made, and the signature or authentic electronic signature of the practitioner. Such written certification issued pursuant to subsection B shall expire no later than one year after its issuance unless the practitioner provides in such written certification an earlier expiration.

D. No practitioner shall be prosecuted under § 18.2-248 or 18.2-248.1 for the issuance of a certification for the use of cannabis products for the treatment or to alleviate the symptoms of a patient's diagnosed condition or disease pursuant to a written certification issued pursuant to subsection B. Nothing in this section shall preclude the Board of Medicine from sanctioning a practitioner for failing to properly evaluate or treat a patient's medical condition or otherwise violating the applicable standard of care for evaluating or treating medical conditions.

E. A practitioner who issues a written certification to a patient pursuant to this section shall register with the Board and shall hold sufficient education and training to exercise appropriate professional judgment in the certification of patients. The Board shall not limit the number of patients to whom a practitioner may issue a written certification. The Board may report information to the applicable licensing board on unusual patterns of certifications issued by a practitioner.

F. A patient who has been issued a written certification shall register with the Board or, if such patient is a minor or an incapacitated adult as defined in § 18.2-369, a patient's parent or legal guardian shall register and shall register such patient with the Board. No patient shall be required to physically present the written certification after the initial dispensing by any pharmaceutical processor or cannabis dispensing facility under each written certification, provided that the pharmaceutical processor or cannabis dispensing facility maintains an electronic copy of the written certification.

G. A patient, or, if such patient is a minor or an incapacitated adult as defined in § 18.2-369, such patient's parent or legal guardian, may designate an individual to act as his registered agent for the purposes of receiving cannabis products pursuant to a valid written certification. Such designated individual shall register with the Board. The Board may set a limit on the number of patients for whom any individual is authorized to act as a registered agent.

H. Upon delivery of cannabis oil by a pharmaceutical processor or cannabis dispensing facility to a designated caregiver facility, any employee or contractor of a designated caregiver facility, who is licensed or registered by a health regulatory board and who is authorized to possess, distribute, or administer medications, may accept delivery of the cannabis oil on behalf of a patient or resident for subsequent delivery to the patient or resident and may assist in the administration of the cannabis oil to the patient or resident as necessary.

I. The Board shall promulgate regulations to implement the registration process. Such regulations shall include (i) a mechanism for sufficiently identifying the practitioner issuing the written certification, the patient being treated by the practitioner, his registered agent, and, if such patient is a minor or an incapacitated adult as defined in § 18.2-369, the patient's parent or legal guardian; (ii) a process for ensuring that any changes in the information are reported in an appropriate timeframe; and (iii) a

798 prohibition for the patient to be issued a written certification by more than one practitioner during any
799 given time period.

800 J. Information obtained under the registration process shall be confidential and shall not be subject to
801 the disclosure provisions of the Virginia Freedom of Information Act (§ 2.2-3700 et seq.). However,
802 reasonable access to registry information shall be provided to (i) the Chairmen of the House Committee
803 for Courts of Justice and the Senate Committee on the Judiciary, (ii) state and federal agencies or local
804 law enforcement for the purpose of investigating or prosecuting a specific individual for a specific
805 violation of law, (iii) licensed practitioners or pharmacists, or their agents, for the purpose of providing
806 patient care and drug therapy management and monitoring of drugs obtained by a registered patient, (iv)
807 a pharmaceutical processor or cannabis dispensing facility involved in the treatment of a registered
808 patient, or (v) a registered patient, his registered agent, or, if such patient is a minor or an incapacitated
809 adult as defined in § 18.2-369, the patient's parent or legal guardian, but only with respect to
810 information related to such registered patient.

811 **§ 54.1-3423. Board to issue registration unless inconsistent with public interest; authorization to**
812 **conduct research; application and fees.**

813 A. The Board shall register an applicant to manufacture or distribute controlled substances included
814 in Schedules I through V unless it determines that the issuance of that registration would be inconsistent
815 with the public interest. In determining the public interest, the Board shall consider the following
816 factors:

817 1. Maintenance of effective controls against diversion of controlled substances into other than
818 legitimate medical, scientific, or industrial channels;

819 2. Compliance with applicable state and local law;

820 3. Any convictions of the applicant under any federal and state laws relating to any controlled
821 substance;

822 4. Past experience in the manufacture or distribution of controlled substances, and the existence in
823 the applicant's establishment of effective controls against diversion;

824 5. Furnishing by the applicant of false or fraudulent material in any application filed under this
825 chapter;

826 6. Suspension or revocation of the applicant's federal registration to manufacture, distribute, or
827 dispense controlled substances as authorized by federal law; and

828 7. Any other factors relevant to and consistent with the public health and safety.

829 B. Registration under subsection A does not entitle a registrant to manufacture and distribute
830 controlled substances in Schedule I or II other than those specified in the registration.

831 C. Practitioners must be registered to conduct research or laboratory analysis with controlled
832 substances in Schedules II through VI, ~~tetrahydrocannabinol~~, or marijuana. Practitioners registered under
833 federal law to conduct research with Schedule I substances, other than ~~tetrahydrocannabinol~~ *marijuana*,
834 may conduct research with Schedule I substances within this Commonwealth upon furnishing the
835 evidence of that federal registration.

836 D. The Board may register other persons or entities to possess controlled substances listed on
837 Schedules II through VI upon a determination that (i) there is a documented need, (ii) the issuance of
838 the registration is consistent with the public interest, (iii) the possession and subsequent use of the
839 controlled substances complies with applicable state and federal laws and regulations, and (iv) the
840 subsequent storage, use, and recordkeeping of the controlled substances will be under the general
841 supervision of a licensed pharmacist, practitioner of medicine, osteopathy, podiatry, dentistry, or
842 veterinary medicine as specified in the Board's regulations. The Board shall consider, at a minimum, the
843 factors listed in subsection A of this section in determining whether the registration shall be issued.
844 Notwithstanding the exceptions listed in § 54.1-3422 A, the Board may mandate a controlled substances
845 registration for sites maintaining certain types and quantities of Schedules II through VI controlled
846 substances as it may specify in its regulations. The Board shall promulgate regulations related to
847 requirements or criteria for the issuance of such controlled substances registration, storage, security,
848 supervision, and recordkeeping.

849 E. The Board may register a public or private animal shelter as defined in § 3.2-6500 to purchase,
850 possess, and administer certain Schedule II through VI controlled substances approved by the State
851 Veterinarian for the purpose of euthanizing injured, sick, homeless, and unwanted domestic pets and
852 animals and to purchase, possess, and administer certain Schedule VI drugs and biological products for
853 the purpose of preventing, controlling, and treating certain communicable diseases that failure to control
854 would result in transmission to the animal population in the shelter. Controlled substances used for
855 euthanasia shall be administered only in accordance with protocols established by the State Veterinarian
856 and only by persons trained in accordance with instructions by the State Veterinarian. The list of
857 Schedule VI drugs and biological products used for treatment and prevention of communicable diseases
858 within the shelter shall be determined by the supervising veterinarian of the shelter and the drugs and
859 biological products shall be administered only pursuant to written protocols established or approved by

the supervising veterinarian of the shelter and only by persons who have been trained in accordance with instructions established or approved by the supervising veterinarian. The shelter shall maintain a copy of the approved list of drugs and biological products, written protocols for administering, and training records of those persons administering drugs and biological products on the premises of the shelter.

F. The Board may register a crisis stabilization unit established pursuant to § 37.2-500 or 37.2-601 and licensed by the Department of Behavioral Health and Developmental Services to maintain a stock of Schedule VI controlled substances necessary for immediate treatment of patients admitted to the crisis stabilization unit, which may be accessed and administered by a nurse pursuant to a written or oral order of a prescriber in the absence of a prescriber. Schedule II through Schedule V controlled substances shall only be maintained if so authorized by federal law and Board regulations.

G. The Board may register an entity at which a patient is treated by the use of instrumentation and diagnostic equipment through which images and medical records may be transmitted electronically for the purpose of establishing a bona fide practitioner-patient relationship and is prescribed Schedule II through VI controlled substances when such prescribing is in compliance with federal requirements for the practice of telemedicine and the patient is not in the physical presence of a practitioner registered with the U.S. Drug Enforcement Administration. In determining whether the registration shall be issued, the Board shall consider (i) the factors listed in subsection A, (ii) whether there is a documented need for such registration, and (iii) whether the issuance of the registration is consistent with the public interest.

H. Applications for controlled substances registration certificates and renewals thereof shall be made on a form prescribed by the Board and such applications shall be accompanied by a fee in an amount to be determined by the Board.

I. Upon (i) any change in ownership or control of a business, (ii) any change of location of the controlled substances stock, (iii) the termination of authority by or of the person named as the responsible party on a controlled substances registration, or (iv) a change in the supervising practitioner, if applicable, the registrant or responsible party shall immediately surrender the registration. The registrant shall, within 14 days following surrender of a registration, file a new application and, if applicable, name the new responsible party or supervising practitioner.

§ 54.1-3442.6. Permit to operate pharmaceutical processor or cannabis dispensing facility.

A. No person shall operate a pharmaceutical processor or a cannabis dispensing facility without first obtaining a permit from the Board. The application for such permit shall be made on a form provided by the Board and signed by a pharmacist who will be in full and actual charge of the pharmaceutical processor's dispensing area or cannabis dispensing facility. The Board shall establish an application fee and other general requirements for such application.

B. Each permit shall expire annually on a date determined by the Board in regulation. The number of permits that the Board may issue or renew in any year is limited to one pharmaceutical processor and up to five cannabis dispensing facilities for each health service area established by the Board of Health. Permits shall be displayed in a conspicuous place on the premises of the pharmaceutical processor and cannabis dispensing facility.

C. The Board shall adopt regulations establishing health, safety, and security requirements for pharmaceutical processors and cannabis dispensing facilities. Such regulations shall include requirements for (i) physical standards; (ii) location restrictions; (iii) security systems and controls; (iv) minimum equipment and resources; (v) recordkeeping; (vi) labeling, including the potency of each botanical cannabis product and the amounts recommended by the practitioner or dispensing pharmacist, and packaging; (vii) routine inspections no more frequently than once annually; (viii) processes for safely and securely dispensing and delivering in person cannabis products to a registered patient, his registered agent, or, if such patient is a minor or an incapacitated adult as defined in § 18.2-369, such patient's parent or legal guardian; (ix) dosage limitations for cannabis oil that provide that each dispensed dose of cannabis oil not exceed 10 milligrams of ~~delta-9-tetrahydrocannabinol~~ *tetrahydrocannabinol*; (x) a process for the wholesale distribution of and the transfer of usable cannabis, botanical cannabis, cannabis oil, and cannabis products between pharmaceutical processors, between a pharmaceutical processor and a cannabis dispensing facility, and between cannabis dispensing facilities; (xi) an allowance for the sale of devices for administration of dispensed cannabis products and hemp-based CBD products that meet the applicable standards set forth in state and federal law, including the laboratory testing standards set forth in subsection M; (xii) an allowance for the use and distribution of inert product samples containing no cannabinoids for patient demonstration exclusively at the pharmaceutical processor or cannabis dispensing facility, and not for further distribution or sale, without the need for a written certification; (xiii) a process for acquiring oil from industrial hemp extract and formulating such oil extract with Cannabis plant extract into allowable dosages of cannabis oil; and (xiv) an allowance for the advertising and promotion of the pharmaceutical processor's products and operations, which shall not limit the

921 pharmaceutical processor from the provision of educational material to practitioners who issue written
922 certifications and registered patients. The Board shall also adopt regulations for pharmaceutical
923 processors that include requirements for (a) processes for safely and securely cultivating Cannabis plants
924 intended for producing cannabis products, (b) the secure disposal of agricultural waste, and (c) a process
925 for registering cannabis oil products.

926 D. The Board shall require that, after processing and before dispensing any cannabis products, a
927 pharmaceutical processor shall make a sample available from each batch of cannabis product for testing
928 by an independent laboratory located in Virginia meeting Board requirements. A valid sample size for
929 testing shall be determined by each laboratory and may vary due to sample matrix, analytical method,
930 and laboratory-specific procedures. A minimum sample size of 0.5 percent of individual units for
931 dispensing or distribution from each homogenized batch of cannabis oil is required to achieve a
932 representative cannabis oil sample for analysis. A minimum sample size, to be determined by the
933 certified testing laboratory, from each batch of botanical cannabis is required to achieve a representative
934 botanical cannabis sample for analysis. Botanical cannabis products shall only be tested for the
935 following: total cannabidiol (CBD); total tetrahydrocannabinol (THC); terpenes; pesticide chemical
936 residue; heavy metals; mycotoxins; moisture; and microbiological contaminants. Testing thresholds shall
937 be consistent with generally accepted cannabis industry thresholds. The pharmaceutical processor may
938 remediate cannabis oil that fails any quality testing standard. Following remediation, all remediated
939 cannabis oil shall be subject to laboratory testing and approved upon satisfaction of testing standards
940 applied to cannabis oil generally. If the batch fails retesting, it shall be considered usable cannabis and
941 may be processed into cannabis oil, unless the failure is related to pesticide requirements, in which case
942 the batch shall not be considered usable cannabis and shall not be processed into cannabis oil. Stability
943 testing shall not be required for any cannabis oil product with an expiration date assigned by the
944 pharmaceutical processor of six months or less from the date of packaging.

945 E. A laboratory testing samples for a pharmaceutical processor shall obtain a controlled substances
946 registration certificate pursuant to § 54.1-3423 and shall comply with quality standards established by the
947 Board in regulation.

948 F. Every pharmaceutical processor's dispensing area or cannabis dispensing facility shall be under the
949 personal supervision of a licensed pharmacist on the premises of the pharmaceutical processor or
950 cannabis dispensing facility. The pharmaceutical processor shall ensure that security measures are
951 adequate to protect the cannabis from diversion at all times, and the pharmacist-in-charge shall have
952 concurrent responsibility for preventing diversion from the dispensing area.

953 Every pharmaceutical processor shall designate a person who shall have oversight of the cultivation
954 and production areas of the pharmaceutical processor and shall provide such information to the Board.
955 The Board shall direct all communications related to enforcement of requirements related to cultivation
956 and production of cannabis oil products by the pharmaceutical processor to such designated person.

957 G. The Board shall require the material owners of an applicant for a pharmaceutical processor or
958 cannabis dispensing facility permit to submit to fingerprinting and provide personal descriptive
959 information to be forwarded along with his fingerprints through the Central Criminal Records Exchange
960 to the Federal Bureau of Investigation for the purpose of obtaining criminal history record information
961 regarding the applicant's material owners. The cost of fingerprinting and the criminal history record
962 search shall be paid by the applicant. The Central Criminal Records Exchange shall forward the results
963 of the criminal history background check to the Board or its designee, which shall be a governmental
964 entity. A pharmaceutical processor shall maintain evidence of criminal background checks for all
965 employees and delivery agents of the pharmaceutical processor. Criminal background checks of
966 employees and delivery agents may be conducted by any service sufficient to disclose any federal and
967 state criminal convictions.

968 H. In addition to other employees authorized by the Board, a pharmaceutical processor may employ
969 individuals who may have less than two years of experience (i) to perform cultivation-related duties
970 under the supervision of an individual who has received a degree in a field related to the cultivation of
971 plants or a certification recognized by the Board or who has at least two years of experience cultivating
972 plants, (ii) to perform extraction-related duties under the supervision of an individual who has a degree
973 in chemistry or pharmacology or at least two years of experience extracting chemicals from plants, and
974 (iii) to perform duties at the pharmaceutical processor and cannabis dispensing facility upon certification
975 as a pharmacy technician.

976 I. A pharmaceutical processor to whom a permit has been issued by the Board may establish up to
977 five cannabis dispensing facilities for the dispensing of cannabis products that have been cultivated and
978 produced on the premises of a pharmaceutical processor permitted by the Board. Each cannabis
979 dispensing facility shall be located within the same health service area as the pharmaceutical processor.

980 J. No person who has been convicted of a felony under the laws of the Commonwealth or another
981 jurisdiction within the last five years shall be employed by or act as an agent of a pharmaceutical
982 processor or cannabis dispensing facility.

983 K. Every pharmaceutical processor or cannabis dispensing facility shall adopt policies for
984 pre-employment drug screening and regular, ongoing, random drug screening of employees.

985 L. A pharmacist at the pharmaceutical processor's dispensing area and the cannabis dispensing facility
986 shall determine the number of pharmacy interns, pharmacy technicians, and pharmacy technician trainees
987 who can be safely and competently supervised at one time; however, no pharmacist shall supervise more
988 than six persons performing the duties of a pharmacy technician at one time in the pharmaceutical
989 processor's dispensing area or cannabis dispensing facility.

990 M. A pharmaceutical processor may acquire industrial hemp extract processed in Virginia, and in
991 compliance with state or federal law, from a registered industrial hemp dealer or processor. A
992 pharmaceutical processor may process and formulate such extract with cannabis plant extract into an
993 allowable dosage of cannabis oil. Industrial hemp extract acquired by a pharmaceutical processor is
994 subject to the same third-party testing requirements that may apply to cannabis plant extract. Testing
995 shall be performed by a laboratory located in Virginia and in compliance with state law. The industrial
996 hemp dealer or processor shall provide such third-party testing results to the pharmaceutical processor
997 before industrial hemp extract may be acquired.

998 N. With the exception of § 2.2-4031, neither the provisions of the Administrative Process Act
999 (§ 2.2-4000 et seq.) nor public participation guidelines adopted pursuant thereto shall apply to the
1000 adoption of any regulation pursuant to this section. Prior to adopting any regulation pursuant to this
1001 section, the Board of Pharmacy shall publish a notice of opportunity to comment in the Virginia
1002 Register of Regulations and post the action on the Virginia Regulatory Town Hall. Such notice of
1003 opportunity to comment shall contain (i) a summary of the proposed regulation; (ii) the text of the
1004 proposed regulation; and (iii) the name, address, and telephone number of the agency contact person
1005 responsible for receiving public comments. Such notice shall be made at least 60 days in advance of the
1006 last date prescribed in such notice for submittals of public comment. The legislative review provisions of
1007 subsections A and B of § 2.2-4014 shall apply to the promulgation or final adoption process for
1008 regulations pursuant to this section. The Board of Pharmacy shall consider and keep on file all public
1009 comments received for any regulation adopted pursuant to this section.

1010 O. The Board shall register all cannabis products that meet testing, labeling, and packaging standards.

1011 **§ 54.1-3442.7. Dispensing cannabis products; report.**

1012 A. A pharmaceutical processor or cannabis dispensing facility shall dispense or deliver cannabis
1013 products only in person to (i) a patient who is a Virginia resident or temporarily resides in Virginia as
1014 made evident to the Board, has been issued a valid written certification, and is registered with the Board
1015 pursuant to § 54.1-3408.3; (ii) such patient's registered agent; or (iii) if such patient is a minor or an
1016 incapacitated adult as defined in § 18.2-369, such patient's parent or legal guardian who is a Virginia
1017 resident or temporarily resides in Virginia as made evident to the Board and is registered with the Board
1018 pursuant to § 54.1-3408.3. A companion may accompany a registered patient into a pharmaceutical
1019 processor's dispensing area or cannabis dispensing facility. Prior to the initial dispensing of cannabis oil
1020 pursuant to each written certification, a pharmacist or pharmacy technician employed by the
1021 pharmaceutical processor or cannabis dispensing facility shall make and maintain, on site or remotely by
1022 electronic means, for two years a paper or electronic copy of the written certification that provides an
1023 exact image of the document that is clearly legible; shall view, in person or by audiovisual means, a
1024 current photo identification of the patient, registered agent, parent, or legal guardian; and shall verify
1025 current board registration of the practitioner and the corresponding patient, registered agent, parent, or
1026 legal guardian. Thereafter, an initial dispensing may be delivered to the patient, registered agent, parent,
1027 legal guardian, or designated caregiver facility. Prior to any subsequent dispensing of cannabis oil
1028 pursuant to each written certification, an employee or delivery agent shall view a current photo
1029 identification of the patient, registered agent, or legal guardian and the current board registration issued
1030 to the patient, registered agent, parent, or legal guardian. No pharmaceutical processor or cannabis
1031 dispensing facility shall dispense more than a 90-day supply of a cannabis product, as determined by the
1032 dispensing pharmacist or certifying practitioner, for any patient during any 90-day period; however, a
1033 pharmaceutical processor or cannabis dispensing facility may dispense more than one cannabis product
1034 to a patient at one time. No more than four ounces of botanical cannabis shall be dispensed for each
1035 30-day period for which botanical cannabis is dispensed. A pharmaceutical processor or cannabis
1036 dispensing facility may dispense less than a 90-day supply. In determining the appropriate amount of a
1037 cannabis product to be dispensed to a patient, a pharmaceutical processor or cannabis dispensing facility
1038 shall consider all cannabis products dispensed to the patient and adjust the amount dispensed
1039 accordingly.

1040 B. A pharmaceutical processor or cannabis dispensing facility shall dispense only cannabis products
1041 produced on the premises of a pharmaceutical processor permitted by the Board or cannabis oil that has
1042 been formulated with oil from industrial hemp acquired by a pharmaceutical processor from a registered
1043 industrial hemp dealer or processor pursuant to § 54.1-3442.6. A pharmaceutical processor may begin

1044 cultivation upon being issued a permit by the Board.

1045 C. The Board shall report annually by December 1 to the Chairmen of the House Committee for
1046 Health, Welfare and Institutions and the Senate Committee on Education and Health on the operation of
1047 pharmaceutical processors and cannabis dispensing facilities issued a permit by the Board, including the
1048 number of practitioners, patients, registered agents, and parents or legal guardians of patients who have
1049 registered with the Board and the number of written certifications issued pursuant to § 54.1-3408.3.

1050 D. The concentration of ~~delta-9-tetrahydrocannabinol~~ *tetrahydrocannabinol* in any cannabis product
1051 on site may be up to 10 percent greater than or less than the level of ~~delta-9-tetrahydrocannabinol~~
1052 *tetrahydrocannabinol* measured for labeling. A pharmaceutical processor and cannabis dispensing facility
1053 shall ensure that such concentration in any cannabis product on site is within such range. A
1054 pharmaceutical processor producing cannabis products shall establish a stability testing schedule of
1055 cannabis products.

1056 **§ 54.1-3446. Schedule I.**

1057 The controlled substances listed in this section are included in Schedule I:

1058 1. Any of the following opiates, including their isomers, esters, ethers, salts, and salts of isomers,
1059 esters, and ethers, unless specifically excepted, whenever the existence of these isomers, esters, ethers
1060 and salts is possible within the specific chemical designation:

1061 1-[2-methyl-4-(3-phenyl-2-propen-1-yl)-1-piperazinyl]-1-butanone (other name: 2-methyl AP-237);

1062 1-(2-phenylethyl)-4-phenyl-4-acetyloxypiperidine (other name: PEPAP);

1063 1-methyl-4-phenyl-4-propionoxypiperidine (other name: MPPP);

1064 2-methoxy-N-phenyl-N-[1-(2-phenylethyl)-4-piperidinyl]-acetamide (other name: Methoxyacetyl
1065 fentanyl);

1066 3,4-dichloro-N-[2-(dimethylamino)cyclohexyl]-N-methyl-benzamide (other name: U-47700);

1067 3,4-dichloro-N-[[1-(dimethylamino)cyclohexyl]methyl]benzamide (other name: AH-7921);

1068 Acetyl fentanyl (other name: desmethyl fentanyl);

1069 Acetylmethadol;

1070 Allylprodine;

1071 Alphacetylmethadol (except levo-alphacetylmethadol, also known as levo-alpha-acetylmethadol,
1072 levomethadyl acetate, or LAAM);

1073 Alphameprodine;

1074 Alphamethadol;

1075 Benzethidine;

1076 Betacetylmethadol;

1077 Betameprodine;

1078 Betamethadol;

1079 Betaprodine;

1080 Clonitazene;

1081 Dextromoramide;

1082 Diampromide;

1083 Diethylthiambutene;

1084 Difenoquin;

1085 Dimenoxadol;

1086 Dimepheptanol;

1087 Dimethylthiambutene;

1088 Dioxaphetylbutyrate;

1089 Dipipanone;

1090 Ethylmethylthiambutene;

1091 Etonitazene;

1092 Etoxadine;

1093 Furethidine;

1094 Hydroxypethidine;

1095 Ketobemidone;

1096 Levomoramide;

1097 Levophenacetylmorphan;

1098 Morpheridine;

1099 MT-45 (1-cyclohexyl-4-(1,2-diphenylethyl)piperazine);

1100 N-(1-phenethylpiperidin-4-yl)-N-phenylcyclopropanecarboxamide (other name: Cyclopropyl fentanyl);

1101 N-(1-phenethylpiperidin-4-yl)-N-phenyltetrahydrofuran-2-carboxamide (other name: Tetrahydrofuranyl
1102 fentanyl);

1103 N-[1-[1-methyl-2-(2-thienyl)ethyl]-4-piperidyl]-N-phenylpropanamide (other name:
1104 alpha-methylthiofentanyl);

1105 N-[1-(1-methyl-2-phenylethyl)-4-piperidyl]-N-phenylacetamide (other name:

- 1106 acetyl-alpha-methylfentanyl);
 1107 N-{1-[2-hydroxy-2-(2-thienyl)ethyl]-4-piperidinyl}-N-phenylpropanamide (other name:
 1108 beta-hydroxythiofentanyl);
 1109 N-[1-(2-hydroxy-2-phenyl)ethyl-4-piperidyl]-N-phenylpropanamide (other name:
 1110 beta-hydroxyfentanyl);
 1111 N-[1-(alpha-methyl-beta-phenyl)ethyl-4-piperidyl]propionanilide (other names:
 1112 1-(1-methyl-2-phenylethyl)-4-(N-propanilido) piperidine, alpha-methylfentanyl);
 1113 N-(2-fluorophenyl)-N-[1-(2-phenylethyl)-4-piperidinyl]-propanamide (other names: 2-fluorofentanyl,
 1114 ortho-fluorofentanyl);
 1115 N-(3-fluorophenyl)-N-[1-(2-phenylethyl)-4-piperidinyl]-propanamide (other name: 3-fluorofentanyl);
 1116 N-[3-methyl-1-(2-hydroxy-2-phenylethyl)-4-piperidyl]-N-phenylpropanamide (other name:
 1117 beta-hydroxy-3-methylfentanyl);
 1118 N-[3-methyl-1-(2-phenylethyl)-4-piperidyl]-N-phenylpropanamide (other name: 3-methylfentanyl);
 1119 N-[3-methyl-1-(2-thienyl)ethyl-4-piperidinyl]-N-phenylpropanamide (other name:
 1120 3-methylthiofentanyl);
 1121 N-(4-fluorophenyl)-2-methyl-N-[1-(2-phenylethyl)-4-piperidinyl]-propanamide (other name:
 1122 para-fluoroisobutyl fentanyl);
 1123 N-(4-fluorophenyl)-N-[1-(2-phenylethyl)-4-piperidinyl]-butanamide (other name:
 1124 para-fluorobutylfentanyl);
 1125 N-(4-fluorophenyl)-N-1-(2-phenylethyl)-4-piperidinyl]-propanamide (other name: para-fluorofentanyl);
 1126 N,N-diethyl-2-(2-(4-isopropoxybenzyl)-5-nitro-1H-benzimidazol-1-yl)ethan-1-amine (other name:
 1127 Isotonitazene);
 1128 N-phenyl-N-[1-(2-phenylmethyl)-4-piperidinyl]-2-furancarboxamide (other name: N-benzyl Furanyl
 1129 norfentanyl);
 1130 N-phenyl-N-(4-piperidinyl)-propanamide (other name: Norfentanyl);
 1131 Noracymethadol;
 1132 Norlevorphanol;
 1133 Normethadone;
 1134 Norpipanone;
 1135 N-phenyl-N-[1-(2-phenylethyl)-4-piperidinyl]-2-furancarboxamide (other name: Furanyl fentanyl);
 1136 N-phenyl-N-[1-(2-phenylethyl)-4-piperidinyl]-2-propenamide (other name: Acryl fentanyl);
 1137 N-phenyl-N-[1-(2-phenylethyl)-4-piperidinyl]-butanamide (other name: butyl fentanyl);
 1138 N-phenyl-N-[1-(2-phenylethyl)-4-piperidinyl]-pentanamide (other name: Pentanoyl fentanyl);
 1139 N-phenyl-N-[1-(2-thienyl)ethyl-4-piperidinyl]-propanamide (other name: thiofentanyl);
 1140 Phenadoxone;
 1141 Phenampromide;
 1142 Phenomorphan;
 1143 Phenoperidine;
 1144 Piritramide;
 1145 Proheptazine;
 1146 Properidine;
 1147 Propiram;
 1148 Racemoramide;
 1149 Tilidine;
 1150 Trimeperidine;
 1151 N-phenyl-N-[1-(2-phenylethyl)-4-piperidinyl]-1,3-benzodioxole-5-carboxamide (other name:
 1152 Benzodioxole fentanyl);
 1153 3,4-dichloro-N-[2-(diethylamino)cyclohexyl]-N-methylbenzamide (other name: U-49900);
 1154 2-(2,4-dichlorophenyl)-N-[2-(dimethylamino)cyclohexyl]-N-methyl acetamide (other name: U-48800);
 1155 2-(3,4-dichlorophenyl)-N-[2-(dimethylamino)cyclohexyl]-N-methyl acetamide (other name: U-51754);
 1156 N-(2-fluorophenyl)-2-methoxy-N-[1-(2-phenylethyl)-4-piperidinyl]-acetamide (other name: Ocfentanil);
 1157 N-(4-methoxyphenyl)-N-[1-(2-phenylethyl)-4-piperidinyl]-butanamide (other name:
 1158 4-methoxybutylfentanyl);
 1159 N-phenyl-2-methyl-N-[1-(2-phenylethyl)-4-piperidinyl]-propanamide (other name: Isobutyl fentanyl);
 1160 N-phenyl-N-[1-(2-phenylethyl)-4-piperidinyl]-cyclopentanecarboxamide (other name: Cyclopentyl
 1161 fentanyl);
 1162 N-phenyl-N-(1-methyl-4-piperidinyl)-propanamide (other name: N-methyl norfentanyl);
 1163 N-[2-(dimethylamino)cyclohexyl]-N-methyl-1,3-benzodioxole-5-carboxamide (other names:
 1164 3,4-methylenedioxy U-47700 or 3,4-MDO-U-47700);
 1165 N-phenyl-N-[1-(2-phenylethyl)-4-piperidinyl]-2-butenamide (other name: Crotonyl fentanyl);
 1166 N-phenyl-N-[4-phenyl-1-(2-phenylethyl)-4-piperidinyl]-propanamide (other name: 4-phenylfentanyl);

- 1167 N-phenyl-N-[1-(2-phenylethyl)-4-piperidiny]-benzamide (other names: Phenyl fentanyl, Benzoyl
 1168 fentanyl);
 1169 N-[2-(dimethylamino)cyclohexyl]-N-phenylfuran-2-carboxamide (other name: Furanyl UF-17);
 1170 N-[2-(dimethylamino)cyclohexyl]-N-phenylpropionamide (other name: UF-17);
 1171 3,4-dichloro-N-[2-(dimethylamino)cyclohexyl]-N-isopropyl-benzamide (other name: Isopropyl
 1172 U-47700).
 1173 2. Any of the following opium derivatives, their salts, isomers and salts of isomers, unless
 1174 specifically excepted, whenever the existence of these salts, isomers and salts of isomers is possible
 1175 within the specific chemical designation:
 1176 Acetorphine;
 1177 Acetyldihydrocodeine;
 1178 Benzylmorphine;
 1179 Codeine methylbromide;
 1180 Codeine-N-Oxide;
 1181 Cyprenorphine;
 1182 Desomorphine;
 1183 Dihydromorphine;
 1184 Drotebanol;
 1185 Etorphine;
 1186 Heroin;
 1187 Hydromorphanol;
 1188 Methyldesorphine;
 1189 Methyldihydromorphine;
 1190 Morphine methylbromide;
 1191 Morphine methylsulfonate;
 1192 Morphine-N-Oxide;
 1193 Myrophine;
 1194 Nicocodeine;
 1195 Nicomorphine;
 1196 Normorphine;
 1197 Pholcodine;
 1198 Thebacon.
 1199 3. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture,
 1200 or preparation, which contains any quantity of the following hallucinogenic substances, or which
 1201 contains any of its salts, isomers, and salts of isomers, whenever the existence of such salts, isomers,
 1202 and salts of isomers is possible within the specific chemical designation (for purposes of this subdivision
 1203 only, the term "isomer" includes the optical, position, and geometric isomers):
 1204 Alpha-ethyltryptamine (some trade or other names: Monase; a-ethyl-1H-indole-3-ethanamine;
 1205 3-2-aminobutyl] indole; a-ET; AET);
 1206 4-Bromo-2,5-dimethoxyphenethylamine (some trade or other names:
 1207 2-4-bromo-2,5-dimethoxyphenyl]-1-aminoethane; alpha-desmethyl DOB; 2C-B; Nexus);
 1208 3,4-methylenedioxy amphetamine;
 1209 5-methoxy-3,4-methylenedioxy amphetamine;
 1210 3,4,5-trimethoxy amphetamine;
 1211 Alpha-methyltryptamine (other name: AMT);
 1212 Bufotenine;
 1213 Diethyltryptamine;
 1214 Dimethyltryptamine;
 1215 4-methyl-2,5-dimethoxyamphetamine;
 1216 2,5-dimethoxy-4-ethylamphetamine (DOET);
 1217 4-fluoro-N-ethylamphetamine;
 1218 2,5-dimethoxy-4-(n)-propylthiophenethylamine (other name: 2C-T-7);
 1219 Ibogaine;
 1220 5-methoxy-N,N-diisopropyltryptamine (other name: 5-MeO-DIPT);
 1221 Lysergic acid diethylamide;
 1222 Mescaline;
 1223 Parahexyl (some trade or other names:
 1224 3-Hexyl-1-hydroxy-7,8,9,10-tetrahydro-6,6,9-trimethyl-6H-dibenzo [b,d] pyran; Synhexyl);
 1225 Peyote;
 1226 N-ethyl-3-piperidyl benzilate;
 1227 N-methyl-3-piperidyl benzilate;
 1228 Psilocybin;

1229 Psilocyn;
 1230 Salvinorin A;
 1231 Tetrahydrocannabinols, except as present in (i) industrial hemp, as defined in § 3.2-4112, that is
 1232 possessed by a person registered pursuant to subsection A of § 3.2-4115 or his agent; (ii) a hemp
 1233 product, as defined in § 3.2-4112, containing a tetrahydrocannabinol concentration of no greater than 0.3
 1234 percent that is derived from industrial hemp, as defined in § 3.2-4112, that is grown, dealt, or processed
 1235 in compliance with state or federal law; (iii) marijuana; (iv) dronabinol in sesame oil and encapsulated
 1236 in a soft gelatin capsule in a drug product approved by the U.S. Food and Drug Administration; or (v)
 1237 industrial hemp, as defined in § 3.2-4112, that is possessed by a person who holds a hemp producer
 1238 license issued by the U.S. Department of Agriculture pursuant to 7 C.F.R. Part 990;
 1239 2,5-dimethoxyamphetamine (some trade or other names: 2,5-dimethoxy-a-methylphenethylamine;
 1240 2,5-DMA);
 1241 3,4-methylenedioxymethamphetamine (MDMA), its optical, positional and geometric isomers, salts
 1242 and salts of isomers;
 1243 3,4-methylenedioxy-N-ethylamphetamine (also known as N-ethyl-alpha-methyl-3,4
 1244 (methylenedioxy)phenethylamine, N-ethyl MDA, MDE, MDEA);
 1245 N-hydroxy-3,4-methylenedioxyamphetamine (some other names:
 1246 N-hydroxy-alpha-methyl-3,4(methylenedioxy)phenethylamine, and N-hydroxy MDA);
 1247 4-bromo-2,5-dimethoxyamphetamine (some trade or other names:
 1248 4-bromo-2,5-dimethoxy-a-methylphenethylamine; 4-bromo-2,5-DMA);
 1249 4-methoxyamphetamine (some trade or other names: 4-methoxy-a-methylphenethylamine;
 1250 paramethoxyamphetamine; PMA);
 1251 Ethylamine analog of phencyclidine (some other names: N-ethyl-1-phenylcyclohexylamine,
 1252 (1-phenylcyclohexyl) ethylamine, N-(1-phenylcyclohexyl) ethylamine, cyclohexamine, PCE);
 1253 Pyrrolidine analog of phencyclidine (some other names: 1-(1-phenylcyclohexyl)-pyrrolidine, PCPy,
 1254 PHP);
 1255 Thiophene analog of phencyclidine (some other names: 1-[1-(2-thienyl)-cyclohexyl]-piperidine,
 1256 2-thienyl analog of phencyclidine, TPCP, TCP);
 1257 1-1-(2-thienyl)cyclohexylpyrrolidine (other name: TCPy);
 1258 3,4-methylenedioxypropylvalerone (other name: MDPV);
 1259 4-methylmethcathinone (other names: mephedrone, 4-MMC);
 1260 3,4-methylenedioxymethcathinone (other name: methylone);
 1261 Naphthylpyrovalerone (other name: naphyrone);
 1262 4-fluoromethcathinone (other names: flephedrone, 4-FMC);
 1263 4-methoxymethcathinone (other names: methedrone; bk-PMMA);
 1264 Ethcathinone (other name: N-ethylcathinone);
 1265 3,4-methylenedioxyethcathinone (other name: ethylone);
 1266 Beta-keto-N-methyl-3,4-benzodioxolylbutanamine (other name: butylone);
 1267 N,N-dimethylcathinone (other name: metamfepramone);
 1268 Alpha-pyrrolidinopropiophenone (other name: alpha-PPP);
 1269 4-methoxy-alpha-pyrrolidinopropiophenone (other name: MOPPP);
 1270 3,4-methylenedioxy-alpha-pyrrolidinopropiophenone (other name: MDPPP);
 1271 Alpha-pyrrolidinovalerophenone (other name: alpha-PVP);
 1272 6,7-dihydro-5H-indeno-(5,6-d)-1,3-dioxol-6-amine (other name: MDAI);
 1273 3-fluoromethcathinone (other name: 3-FMC);
 1274 4-Ethyl-2,5-dimethoxyphenethylamine (other name: 2C-E);
 1275 4-Iodo-2,5-dimethoxyphenethylamine (other name: 2C-I);
 1276 4-Methylethcathinone (other name: 4-MEC);
 1277 4-Ethylmethcathinone (other name: 4-EMC);
 1278 N,N-diallyl-5-methoxytryptamine (other name: 5-MeO-DALT);
 1279 Beta-keto-methylbenzodioxolylpentanamine (other names: Pentylone, bk-MBDP);
 1280 Alpha-methylamino-butyrophenone (other name: Buphedrone);
 1281 Alpha-methylamino-valerophenone (other name: Pentedrone);
 1282 3,4-Dimethylmethcathinone (other name: 3,4-DMMC);
 1283 4-methyl-alpha-pyrrolidinopropiophenone (other name: MPPP);
 1284 4-Iodo-2,5-dimethoxy-N-[(2-methoxyphenyl)methyl]-benzeneethanamine (other names: 25-I,
 1285 25I-NBOMe, 2C-I-NBOMe);
 1286 Methoxetamine (other names: MXE, 3-MeO-2-Oxo-PCE);
 1287 4-Fluoromethamphetamine (other name: 4-FMA);
 1288 4-Fluoroamphetamine (other name: 4-FA);
 1289 2-(2,5-Dimethoxy-4-methylphenyl)ethanamine (other name: 2C-D);

- 1290 2-(4-Chloro-2,5-dimethoxyphenyl)ethanamine (other name: 2C-C);
- 1291 2-[4-(Ethylthio)-2,5-dimethoxyphenyl]ethanamine (other name: 2C-T-2);
- 1292 2-[4-(Isopropylthio)-2,5-dimethoxyphenyl]ethanamine (other name: 2C-T-4);
- 1293 2-(2,5-Dimethoxyphenyl)ethanamine (other name: 2C-H);
- 1294 2-(2,5-Dimethoxy-4-nitro-phenyl)ethanamine (other name: 2C-N);
- 1295 2-(2,5-Dimethoxy-4-(n)-propylphenyl)ethanamine (other name: 2C-P);
- 1296 (2-aminopropyl)benzofuran (other name: APB);
- 1297 (2-aminopropyl)-2,3-dihydrobenzofuran (other name: APDB);
- 1298 4-chloro-2,5-dimethoxy-N-[(2-methoxyphenyl)methyl]-benzeneethanamine (other names:
- 1299 2C-C-NBOMe, 25C-NBOMe, 25C);
- 1300 4-bromo-2,5-dimethoxy-N-[(2-methoxyphenyl)methyl]-benzeneethanamine (other names:
- 1301 2C-B-NBOMe, 25B-NBOMe, 25B);
- 1302 Acetoxymethyltryptamine (other names: AcO-Psilocin, AcO-DMT, Psilacetin);
- 1303 Benocyclidine (other names: BCP, BTCP);
- 1304 Alpha-pyrrolidinobutiophenone (other name: alpha-PBP);
- 1305 3,4-methylenedioxy-N,N-dimethylcathinone (other names: Dimethylone, bk-MDDMA);
- 1306 4-bromomethcathinone (other name: 4-BMC);
- 1307 4-chloromethcathinone (other name: 4-CMC);
- 1308 4-Iodo-2,5-dimethoxy-N-[(2-hydroxyphenyl)methyl]-benzeneethanamine (other name: 25I-NBOH);
- 1309 Alpha-Pyrrolidinohexiophenone (other name: alpha-PHP);
- 1310 Alpha-Pyrrolidinoheptiophenone (other name: PV8);
- 1311 5-methoxy-N,N-methylisopropyltryptamine (other name: 5-MeO-MIPT);
- 1312 Beta-keto-N,N-dimethylbenzodioxolylbutanamine (other names: Dibutylone, bk-DMBDB);
- 1313 Beta-keto-4-bromo-2,5-dimethoxyphenethylamine (other name: bk-2C-B);
- 1314 1-(1,3-benzodioxol-5-yl)-2-(ethylamino)-1-pentanone (other name: N-ethylpentylone);
- 1315 1-[1-(3-methoxyphenyl)cyclohexyl]piperidine (other name: 3-methoxy PCP);
- 1316 1-[1-(4-methoxyphenyl)cyclohexyl]piperidine (other name: 4-methoxy PCP);
- 1317 4-Chloroethcathinone (other name: 4-CEC);
- 1318 3-Methoxy-2-(methylamino)-1-(4-methylphenyl)-1-propanone (other name: Mexedrone);
- 1319 1-propionyl lysergic acid diethylamide (other name: 1P-LSD);
- 1320 (2-Methylaminopropyl)benzofuran (other name: MAPB);
- 1321 1-(1,3-benzodioxol-5-yl)-2-(dimethylamino)-1-pentanone (other names: N,N-Dimethylpentylone,
- 1322 Dipentylone);
- 1323 1-(4-methoxyphenyl)-2-(pyrrolidin-1-yl)octan-1-one (other name: 4-methoxy-PV9);
- 1324 3,4-tetramethylene-alpha-pyrrolidinovalerophenone (other name: TH-PVP);
- 1325 4-allyloxy-3,5-dimethoxyphenethylamine (other name: Allylescaline);
- 1326 4-Bromo-2,5-dimethoxy-N-[(2-hydroxyphenyl)methyl]-benzeneethanamine (other name: 25B-NBOH);
- 1327 4-chloro-alpha-methylamino-valerophenone (other name: 4-chloropentedrone);
- 1328 4-chloro-alpha-Pyrrolidinovalerophenone (other name: 4-chloro-alpha-PVP);
- 1329 4-fluoro-alpha-Pyrrolidinoheptiophenone (other name: 4-fluoro-PV8);
- 1330 4-hydroxy-N,N-diisopropyltryptamine (other name: 4-OH-DIPT);
- 1331 4-methyl-alpha-ethylaminopentiophenone;
- 1332 4-methyl-alpha-Pyrrolidinohexiophenone (other name: MPHP);
- 1333 5-methoxy-N,N-dimethyltryptamine (other name: 5-MeO-DMT);
- 1334 5-methoxy-N-ethyl-N-isopropyltryptamine (other name: 5-MeO-EIPT);
- 1335 6-ethyl-6-nor-lysergic acid diethylamide (other name: ETH-LAD);
- 1336 6-allyl-6-nor-lysergic acid diethylamide (other name: AL-LAD);
- 1337 (N-methyl aminopropyl)-2,3-dihydrobenzofuran (other name: MAPDB);
- 1338 2-(methylamino)-2-phenyl-cyclohexanone (other name: Deschloroketamine);
- 1339 2-(ethylamino)-2-phenyl-cyclohexanone (other name: deschloro-N-ethyl-ketamine);
- 1340 2-methyl-1-(4-(methylthio)phenyl)-2-morpholinopropiophenone (other name: MMMP);
- 1341 Alpha-ethylaminohexanophenone (other name: N-ethylhexedrone);
- 1342 N-ethyl-1-(3-methoxyphenyl)cyclohexylamine (other name: 3-methoxy-PCE);
- 1343 4-fluoro-alpha-pyrrolidinohexiophenone (other name: 4-fluoro-alpha-PHP);
- 1344 N-ethyl-1,2-diphenylethylamine (other name: Ephenedine);
- 1345 2,5-dimethoxy-4-chloroamphetamine (other name: DOC);
- 1346 3,4-methylenedioxy-N-tert-butylcathinone;
- 1347 Alpha-pyrrolidinoisohexiophenone (other name: alpha-PiHP);
- 1348 1-[1-(3-hydroxyphenyl)cyclohexyl]piperidine (other name: 3-hydroxy PCP);
- 1349 4-acetyloxy-N,N-diallyltryptamine (other name: 4-AcO-DALT);
- 1350 4-hydroxy-N,N-methylisopropyltryptamine (other name: 4-hydroxy-MIPT);
- 1351 3,4-Methylenedioxy-alpha-pyrrolidinohexanophenone (other name: MDPHP);

- 1352 5-methoxy-N,N-dibutyltryptamine (other name: 5-methoxy-DBT);
- 1353 1-(1,3-benzodioxol-5-yl)-2-(ethylamino)-1-butanone (other names: Eutylone, bk-EBDB);
- 1354 1-(1,3-benzodioxol-5-yl)-2-(butylamino)-1-pentanone (other name: N-butylpentylone);
- 1355 N-benzyl-3,4-dimethoxyamphetamine (other name: N-benzyl-3,4-DMA);
- 1356 1-(benzo[d][1,3]dioxol-5-yl)-2-(sec-butylamino)pentan-1-one (other name: N-sec-butyl Pentylone);
- 1357 1-cyclopropionyl lysergic acid diethylamide (other name: 1cP-LSD);
- 1358 2-(ethylamino)-1-phenylheptan-1-one (other name: N-ethylheptedrone);
- 1359 (2-ethylaminopropyl)benzofuran (other name: EAPB);
- 1360 4-ethyl-2,5-dimethoxy-N-[(2-hydroxyphenyl)methyl]-benzeneethanamine (other name: 25E-NBOH);
- 1361 2-fluoro-Deschloroketamine (other name: 2-(2-fluorophenyl)-2-(methylamino)-cyclohexanone);
- 1362 4-hydroxy-N-ethyl-N-propyltryptamine (other name: 4-hydroxy-EPT);
- 1363 2-(isobutylamino)-1-phenylhexan-1-one (other names: N-Isobutyl Hexedrone,
- 1364 alpha-isobutylaminohexanphenone);
- 1365 1-(4-methoxyphenyl)-N-methylpropan-2-amine (other names: para-Methoxymethamphetamine,
- 1366 PMMA);
- 1367 N-ethyl-1-(3-hydroxyphenyl)cyclohexylamine (other name: 3-hydroxy-PCE);
- 1368 N-heptyl-3,4-dimethoxyamphetamine (other names: N-heptyl-3,4-DMA);
- 1369 N-hexyl-3,4-dimethoxyamphetamine (other names: N-hexyl-3,4-DMA).
- 1370 4. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture
- 1371 or preparation which contains any quantity of the following substances having a depressant effect on the
- 1372 central nervous system, including its salts, isomers and salts of isomers whenever the existence of such
- 1373 salts, isomers and salts of isomers is possible within the specific chemical designation:
- 1374 Clonazepam;
- 1375 Etizolam;
- 1376 Flualprazolam;
- 1377 Flubromazepam;
- 1378 Flubromazolam;
- 1379 Gamma hydroxybutyric acid (some other names include GHB; gamma hydroxybutyrate;
- 1380 4-hydroxybutyrate; 4-hydroxybutanoic acid; sodium oxybate; sodium oxybutyrate);
- 1381 Mecloqualone;
- 1382 Methaqualone.
- 1383 5. Unless specifically excepted or unless listed in another schedule, any material, compound, mixture
- 1384 or preparation which contains any quantity of the following substances having a stimulant effect on the
- 1385 central nervous system, including its salts, isomers and salts of isomers:
- 1386 2-(3-fluorophenyl)-3-methylmorpholine (other name: 3-fluorophenmetrazine);
- 1387 Aminorex (some trade or other names; aminoxaphen; 2-amino-5-phenyl-2-oxazoline;
- 1388 4,5-dihydro-5-phenyl-2-oxazolamine);
- 1389 Cathinone (some trade or other names: 2-amino-1-phenyl-1-propanone, alpha-aminopropiophenone,
- 1390 2-aminopropiophenone, norephedrone), and any plant material from which Cathinone may be derived;
- 1391 Cis-4-methylaminorex (other name: cis-4,5-dihydro-4-methyl-5-phenyl-2-oxazolamine);
- 1392 Ethylamphetamine;
- 1393 Ethyl phenyl(piperidin-2-yl)acetate (other name: Ethylphenidate);
- 1394 Fenethylamine;
- 1395 Methcathinone (some other names: 2-(methylamino)-propionophenone;
- 1396 alpha-(methylamino)-propionophenone; 2-(methylamino)-1-phenylpropan-1-one;
- 1397 alpha-N-methylaminopropiophenone; monomethylpropion; ephedrone; N-methylcathinone;
- 1398 methylcathinone; AL-464; AL-422; AL-463 and UR 1432);
- 1399 N-Benzylpiperazine (some other names: BZP, 1-benzylpiperazine);
- 1400 N,N-dimethylamphetamine (other names: N, N-alpha-trimethyl-benzeneethanamine, N,
- 1401 N-alpha-trimethylphenethylamine);
- 1402 Methyl 2-(4-fluorophenyl)-2-(2-piperidinyl)acetate (other name: 4-fluoromethylphenidate);
- 1403 Isopropyl-2-phenyl-2-(2-piperidinyl)acetate (other name: Isopropylphenidate);
- 1404 4-chloro-N,N-dimethylcathinone;
- 1405 3,4-methylenedioxy-N-benzylcathinone (other name: BMDP).
- 1406 6. Any substance that contains one or more cannabimimetic agents or that contains their salts,
- 1407 isomers, and salts of isomers whenever the existence of such salts, isomers, and salts of isomers is
- 1408 possible within the specific chemical designation, and any preparation, mixture, or substance containing,
- 1409 or mixed or infused with, any detectable amount of one or more cannabimimetic agents.
- 1410 a. "Cannabimimetic agents" includes any substance that is within any of the following structural
- 1411 classes:
- 1412 2-(3-hydroxycyclohexyl)phenol with substitution at the 5-position of the phenolic ring by alkyl or

- 1413 alkenyl, whether or not substituted on the cyclohexyl ring to any extent;
- 1414 3-(1-naphthoyl)indole or 1H-indol-3-yl-(1-naphthyl)methane with substitution at the nitrogen atom of
- 1415 the indole ring, whether or not further substituted on the indole ring to any extent, whether or not
- 1416 substituted on the naphthoyl or naphthyl ring to any extent;
- 1417 3-(1-naphthoyl)pyrrole with substitution at the nitrogen atom of the pyrrole ring, whether or not
- 1418 further substituted in the pyrrole ring to any extent, whether or not substituted on the naphthoyl ring to
- 1419 any extent;
- 1420 1-(1-naphthylmethyl)indene with substitution of the 3-position of the indene ring, whether or not
- 1421 further substituted in the indene ring to any extent, whether or not substituted on the naphthyl ring to
- 1422 any extent;
- 1423 3-phenylacetylindole or 3-benzoylindole with substitution at the nitrogen atom of the indole ring,
- 1424 whether or not further substituted in the indole ring to any extent, whether or not substituted on the
- 1425 phenyl ring to any extent;
- 1426 3-cyclopropoylindole with substitution at the nitrogen atom of the indole ring, whether or not further
- 1427 substituted on the indole ring to any extent, whether or not substituted on the cyclopropyl ring to any
- 1428 extent;
- 1429 3-adamantoylindole with substitution at the nitrogen atom of the indole ring, whether or not further
- 1430 substituted on the indole ring to any extent, whether or not substituted on the adamantyl ring to any
- 1431 extent;
- 1432 N-(adamantyl)-indole-3-carboxamide with substitution at the nitrogen atom of the indole ring,
- 1433 whether or not further substituted on the indole ring to any extent, whether or not substituted on the
- 1434 adamantyl ring to any extent; and
- 1435 N-(adamantyl)-indazole-3-carboxamide with substitution at a nitrogen atom of the indazole ring,
- 1436 whether or not further substituted on the indazole ring to any extent, whether or not substituted on the
- 1437 adamantyl ring to any extent.
- 1438 b. The term "cannabimimetic agents" includes:
- 1439 5-(1,1-Dimethylheptyl)-2-[3-hydroxycyclohexyl]-phenol (other name: CP 47,497);
- 1440 5-(1,1-Dimethylhexyl)-2-[3-hydroxycyclohexyl]-phenol (other name: CP 47,497 C6 homolog);
- 1441 5-(1,1-Dimethyloctyl)-2-[3-hydroxycyclohexyl]-phenol (other name: CP 47,497 C8 homolog);
- 1442 5-(1,1-Dimethylnonyl)-2-[3-hydroxycyclohexyl]-phenol (other name: CP 47,497 C9 homolog);
- 1443 1-pentyl-3-(1-naphthoyl)indole (other names: JWH-018, AM-678);
- 1444 1-butyl-3-(1-naphthoyl)indole (other name: JWH-073);
- 1445 1-pentyl-3-(2-methoxyphenylacetyl)indole (other name: JWH-250);
- 1446 1-hexyl-3-(naphthalen-1-oyl)indole (other name: JWH-019);
- 1447 1-[2-(4-morpholinyl)ethyl]-3-(1-naphthoyl)indole (other name: JWH-200);
- 1448 (6aR,10aR)-9-(hydroxymethyl)-6,6-dimethyl-3-(2-methyloctan-2-yl)-6a,7,10,10a-tet
- 1449 rahydrobenzo[c]chromen-1-ol (other name: HU-210);
- 1450 1-pentyl-3-(4-methoxy-1-naphthoyl)indole (other name: JWH-081);
- 1451 1-pentyl-3-(4-methyl-1-naphthoyl)indole (other name: JWH-122);
- 1452 1-pentyl-3-(2-chlorophenylacetyl)indole (other name: JWH-203);
- 1453 1-pentyl-3-(4-ethyl-1-naphthoyl)indole (other name: JWH-210);
- 1454 1-pentyl-3-(4-chloro-1-naphthoyl)indole (other name: JWH-398);
- 1455 1-(5-fluoropentyl)-3-(2-iodobenzoyl)indole (other name: AM-694);
- 1456 1-((N-methylpiperidin-2-yl)methyl)-3-(1-naphthoyl)indole (other name: AM-1220);
- 1457 1-(5-fluoropentyl)-3-(1-naphthoyl)indole (other name: AM-2201);
- 1458 1-[(N-methylpiperidin-2-yl)methyl]-3-(2-iodobenzoyl)indole (other name: AM-2233);
- 1459 Pravadoline (4-methoxyphenyl)-[2-methyl-1-(2-(4-morpholinyl)ethyl)indol-3-yl]methanone (other
- 1460 name: WIN 48,098);
- 1461 1-pentyl-3-(4-methoxybenzoyl)indole (other names: RCS-4, SR-19);
- 1462 1-(2-cyclohexylethyl)-3-(2-methoxyphenylacetyl)indole (other names: RCS-8, SR-18);
- 1463 1-pentyl-3-(2,2,3,3-tetramethylcyclopropylmethanone)indole (other name: UR-144);
- 1464 1-(5-fluoropentyl)-3-(2,2,3,3-tetramethylcyclopropylmethanone)indole (other names: XLR-11,
- 1465 5-fluoro-UR-144);
- 1466 N-adamantyl-1-fluoropentylindole-3-carboxamide (other name: STS-135);
- 1467 N-adamantyl-1-pentylindazole-3-carboxamide (other names: AKB48, APINACA);
- 1468 1-pentyl-3-(1-adamantoyl)indole (other name: AB-001);
- 1469 (8-quinolinyl)(1-pentylindol-3-yl)carboxylate (other name: PB-22);
- 1470 (8-quinolinyl)(1-(5-fluoropentyl)indol-3-yl)carboxylate (other name: 5-fluoro-PB-22);
- 1471 (8-quinolinyl)(1-cyclohexylmethyl-indol-3-yl)carboxylate (other name: BB-22);
- 1472 N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-pentylindazole-3-carboxamide (other name: AB-PINACA);
- 1473 N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(4-fluorobenzyl)indazole-3-carboxamide (other name:
- 1474 AB-FUBINACA);

1475 1-(5-fluoropentyl)-3-(1-naphthoyl)indazole (other name: THJ-2201);
 1476 N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-pentylindazole-3-carboxamide (other name:
 1477 ADB-PINACA);
 1478 N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)indazole-3-carboxamide (other name:
 1479 AB-CHMINACA);
 1480 N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)indazole-3-carboxamide (other name:
 1481 5-fluoro-AB-PINACA);
 1482 N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)indazole-3-carboxamide (other
 1483 names: ADB-CHMINACA, MAB-CHMINACA);
 1484 Methyl 2-(1-(5-fluoropentyl)-1H-indazole-3-carboxamido)-3-methylbutanoate (other name:
 1485 5-fluoro-AMB);
 1486 1-naphthalenyl 1-(5-fluoropentyl)-1H-indole-3-carboxylate (other name: NM-2201);
 1487 1-(4-fluorobenzyl)-3-(2,2,3,3-tetramethylcyclopropylmethanone)indole (other name: FUB-144);
 1488 1-(5-fluoropentyl)-3-(4-methyl-1-naphthoyl)indole (other name MAM-2201);
 1489 N-(1-Amino-3,3-dimethyl-1-oxobutan-2-yl)-1-[(4-fluorophenyl)methyl]-1H-indazole- 3-carboxamide
 1490 (other name: ADB-FUBINACA);
 1491 Methyl 2-[1-[(4-fluorophenyl)methyl]-1H-indazole-3-carboxamido]-3,3-di methylbutanoate (other
 1492 name: MDMB-FUBINACA);
 1493 Methyl 2-[1-(5-fluoropentyl)-1H-indazole-3-carboxamido]-3,3-dimethylbutanoate (other names:
 1494 5-fluoro-ADB, 5-Fluoro-MDMB-PINACA);
 1495 Methyl 2-({1-[(4-fluorophenyl)methyl]-1H-indazole-3-carbonyl}amino)-3-methylbutanoat e (other
 1496 names: AMB-FUBINACA, FUB-AMB);
 1497 N-(adamantan-1-yl)-1-(4-fluorobenzyl)-1H-indazole-3-carboxamide (other name: FUB-AKB48);
 1498 N-(adamantan-1-yl)-1-(5-fluoropentyl)-1H-indazole-3-carboxamide (other name: 5F-AKB48);
 1499 N-(adamantanyl)-1-(5-chloropentyl) indazole-3-carboxamide (other name: 5-chloro-AKB48);
 1500 Naphthalen-1-yl 1-pentyl-1H-indazole-3-carboxylate (other name: SDB-005);
 1501 N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(cyclohexylmethyl)indole-3-carboxamide (other name:
 1502 AB-CHMICA);
 1503 1-pentyl-N-(phenylmethyl)-1H-indole-3-carboxamide (other name: SDB-006);
 1504 Quinolin-8-yl 1-(4-fluorobenzyl)-1H-indole-3-carboxylate (other name: FUB-PB-22);
 1505 Methyl N-[1-(cyclohexylmethyl)-1H-indole-3-carbonyl]valinate (other name: MMB-CHMICA);
 1506 N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-(5-fluoropentyl)indazole-3-carboxamid e (other name:
 1507 5-fluoro-ADB-PINACA);
 1508 1-(4-cyanobutyl)-N-(1-methyl-1-phenylethyl)-1H-indazole-3-carboxamide (other name: 4-cyano
 1509 CUMYL-BUTINACA);
 1510 Methyl 2-[1-(5-fluoropentyl)-1H-indole-3-carboxamido]-3,3-dimethylbutanoate (other name:
 1511 5-Fluoro-MDMB-PICA);
 1512 Ethyl 2-({1-[(4-fluorophenyl)methyl]-1H-indazole-3-carbonyl}amino)-3-methylbutanoat e (other name:
 1513 EMB-FUBINACA);
 1514 Methyl 2-[1-4-fluorobutyl)-1H-indazole-3-carboxamido]-3,3-dimethylbutanoate (other name:
 1515 4-fluoro-MDMB-BUTINACA);
 1516 1-(5-fluoropentyl)-N-(1-methyl-1-phenylethyl)-1H-indole-3-carboxamide (other name: 5-fluoro
 1517 CUMYL-PICA);
 1518 Methyl 2-[1-(pent-4-enyl)-1H-indazole-3-carboxamido]-3,3-dimethylbutanoate (other name:
 1519 MDMB-4en-PINACA);
 1520 Methyl 2-({1-[(4-fluorophenyl)methyl]-1H-indole-3-carbonyl}amino)-3-methylbutanoate (other names:
 1521 MMB-FUBICA, AMB-FUBICA);
 1522 Methyl 2-[1-(4-penten-1-yl)-1H-indole-3-carboxamido]-3-methylbutanoate (other names: MMB022,
 1523 MMB-4en-PICA);
 1524 Methyl 2-[1-(5-fluoropentyl)-1H-indole-3-carboxamido]-3-methylbutanoate (other name: MMB 2201);
 1525 Methyl 2-[1-(5-fluoropentyl)-1H-indole-3-carboxamido]-3-phenylpropanoate (other name:
 1526 5-fluoro-MPP-PICA);
 1527 N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-butyldiazole-3-carboxamide (other name:
 1528 ADB-BUTINACA);
 1529 N-(1-amino-3-methyl-1-oxobutan-2-yl)-1-(5-chloropentyl)indazole-3-carboxamide (other name:
 1530 5-chloro-AB-PINACA).

1531 **2. That the provisions of this act amending §§ 54.1-3408.3, 54.1-3442.6, and 54.1-3442.7 of the**
 1532 **Code of Virginia shall become effective when the Virginia Cannabis Control Authority provides**
 1533 **written notice to the Division of Legislative Services that persons are allowed to apply for, obtain,**
 1534 **and fully utilize a license from the Virginia Cannabis Control Authority to sell retail marijuana,**
 1535 **retail marijuana products, immature marijuana plants, and marijuana seeds to the public.**

1536 3. That, notwithstanding any other provision of law, if an act of assembly is passed by the 2022
1537 Session of the General Assembly that establishes a regulatory and licensing structure for the retail
1538 sale of marijuana and marijuana products to persons 21 years of age or older, such regulatory
1539 and licensing requirements that pertain only to retail marijuana or retail marijuana products shall
1540 not apply to industrial hemp extract that (i) is processed by an industrial hemp processor that is
1541 registered with the Commissioner of Agriculture and Consumer Services pursuant to Chapter 41.1
1542 (§ 3.2-4112 et seq.) of Title 3.2 and is operating in compliance with all laws and regulations
1543 governing such processors and manufacturers of edible hemp products operating in accordance
1544 with Article 6 (§ 3.2-5145.6 et seq.) of Chapter 51 of Title 3.2; (ii) does not contain a total
1545 tetrahydrocannabinol concentration that exceeds 0.3 percent at the time such industrial hemp
1546 extract is offered for sale at retail and does not contain more than 0.25 milligram of
1547 tetrahydrocannabinol per serving or more than one milligram per package; and (iii) is tested,
1548 labeled, packaged, and advertised in accordance with any applicable provisions of such act of
1549 assembly or regulations promulgated thereto.